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ABSTRACT 
 
 Receptor tyrosine kinases (RTKs) are the second largest family of 
transmembrane receptors, and these proteins regulate numerous cellular processes 
including cell survival, metabolism, proliferation and differentiation. Mutations that affect 
the activity, abundance, cellular distribution or regulation of these receptors often leads 
to diseases such as cancer, making our understanding of the basic biology of these 
receptors, especially the regulation of their expression and signaling, critically important. 
One such RTK, RET, is a receptor for glial cell line-derived neurotrophic factor (GDNF) 
family ligands (GFLs) and has several functions in the developing embryo, including 
crucial roles in kidney morphogenesis, spermatogenesis and development of numerous 
neuronal populations. Regulation of RET through mechanisms such as intracellular 
trafficking, turnover and activation change the signaling capabilities of RET and have 
been well studied. Here I present two additional novel mechanisms of action of RET.  
 In the first investigation, I explored the effects of novel 5’-alternative splicing on 
RET protein structure and function. These isoforms, which arise from exon skipping, are 
full-length RET proteins with deletions in the extracellular domain and are referred to as 
RETΔE3 and RETΔE345. I found that these isoforms differ from full-length RET in both 
their biochemical properties as well as their signaling capabilities. In the second study, I 
investigated the interaction of RET with p75, a pro-apoptotic protein that is a member of 
the tumor necrosis factor receptor (TNFR) superfamily. While I discovered that RET and 
p75 interact, and that this association is increased by the presence of pro-apoptotic 
	  ix	  
stimuli in vitro, I identified a p75-independent role for RET in programmed cell death in 
the sympathetic nervous system during development in vivo. These data provide two 
novel mechanisms for the regulation of RET which, along with future studies, will further 
our understanding of RET biology under physiologic and pathologic conditions. 
1	  
 
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
 
Receptor tyrosine kinases are a large family of cell surface receptors. 
Receptor tyrosine kinases (RTKs) are a large family of cell surface proteins that 
act as receptors for hormones and growth factors. They are the second largest family of 
transmembrane receptors, the largest being G-protein coupled receptors (GPCRs), and 
are comprised of 58 RTKs that fall into 20 subfamilies (Lodish et al., 2008).  RTKs 
regulate numerous cellular processes such as proliferation and differentiation, cell 
survival and cellular metabolism, and their importance can be appreciated by their high 
conservation between multiple species, from C. elegans to humans (Lemmon and 
Schlessinger, 2010). 
 All RTKs have a similar molecular architecture that includes an extracellular 
ligand-binding region, a single transmembrane α-helix, and an intracellular tyrosine 
kinase domain (Lodish et al., 2008). In the absence of ligand, most RTKs are 
monomeric, and have very low intrinsic kinase activity. Upon ligand binding, two 
receptor monomers are induced to dimerize, allowing the kinase domain of one 
monomer to phosphorylate one or several tyrosine residues in the catalytic site of the 
other monomer (Lodish et al., 2008). This leads to a conformational change in the 
dimeric structure of the proteins, allowing for binding of ATP to some receptors or 
protein substrates in other receptors (Lemmon and Schlessinger, 2010). The resulting 
conformational change enhances the kinase activity of the RTK, causing 
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phosphorylation of additional tyrosine residues in the cytosolic domain of the receptor 
(Lodish et al., 2008).  These phosphorylated tyrosines serve as docking sites for 
additional adaptor molecules and signaling proteins, which trigger activation of multiple 
intracellular signaling pathways (Lemmon and Schlessinger, 2010). However, not all 
RTKs dimerize upon ligand binding – some RTKs, such as the insulin receptor, form 
pre-complexed dimers in the absence of hormone. In this case, binding of the ligand 
insulin alters the conformation of the receptor to allow for its activation (Lodish et al., 
2008). 
RTKs have been widely studied not only due to their important roles throughout 
development, but also because they play numerous roles in diseases due to genetic 
mutations that affect the activity, abundance, cellular distribution or regulation of the 
receptors (Mulligan, 2014). One common theme is that aberrant activation of RTKs are 
causally linked to cancers (Schlessinger, 2014), diabetes (Schlessinger, 2014), 
inflammation (Wang and Hankey, 2013), bone disorders (Segaliny et al., 2015), 
arteriosclerosis (Hopkins, 2013) and angiogenesis (Jeltsch et al., 2013). Understanding 
the basic biology of these receptors and how cells regulate their expression and 
signaling is important to better understand their role in disease.  
 
The receptor tyrosine kinase, RET, is a receptor for glial cell line-derived 
neurotrophic factor (GDNF) family ligands (GFLs).  
RET is a single-pass, type 1 transmembrane receptor tyrosine kinase that is 
conserved from humans to Drosophila melanogaster (Anders et al., 2001). The gene 
encoding RET was first identified in 1985 when DNA from a T cell lymphoma was 
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transfected into NIH/3T3 cells resulting in foci formation (Takahashi et al., 1985). The 
cause of this was a DNA rearrangement that occurred during the transfection process 
resulting in the recombination of two unrelated DNA sequences, and thus the authors 
proposed calling the previously undescribed gene, RET, which is an acronym for 
“REarranged during Transfection.” Although the name RET originally referenced the 
recombined gene, the name was kept to designate the gene coding for the receptor 
tyrosine kinase portion of the original oncogene (Takahashi et al., 1985). 
  RET is activated by and acts as a common receptor for the glial cell line-derived 
neurotrophic factor (GDNF) family ligands (GFLs) (Fig. 1.1), of which there are four: 
GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN) (Airaksinen and 
Saarma, 2002). GDNF was purified in 1993 and characterized as a neurotrophic factor 
for the survival of embryonic dopaminergic neurons in vitro, and in 1996, several groups 
reported that GDNF was the ligand for RET (Lin et al., 1993, Durbec et al., 1996, Trupp 
et al., 1996). The identification of NRTN soon followed when it was discovered that an 
unknown factor in conditioned medium from Chinese hamster ovary (CHO) cells could 
support the survival of sympathetic neurons in culture. Amino acid sequencing indicated 
that this was a novel ligand and was related to GDNF (Kotzbauer et al., 1996). 
Thereafter, ARTN and PSPN were identified by database searches and homology-
based PCR screening (Milbrandt et al., 1998, Baloh et al., 1998). 
Unlike other ligand-RTK signaling complexes, GFLs do not bind directly to RET, 
but first bind to and create a binary complex with one of four cognate 
glycosylphosphatidylinositol (GPI)-anchored co-receptors known as the GDNF Family 
Receptor-αs (GFRα1-4). RET is the only known receptor tyrosine kinase that does not 
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directly bind its ligands. Each ligand has a preferential affinity for one of the GFRαs; 
GDNF binds to GFRα1, NRTN binds to GFRα2, ARTN binds to GFRα3, and PSPN 
binds to GFRα4 (Airaksinen and Saarma, 2002). Upon associating, the GFL-GFRα 
complex binds to RET, recruiting it into a cholesterol-rich membrane subdomain known 
as a lipid raft (Tansey et al., 2000, Paratcha et al., 2001, Ledda et al., 2002). Here, RET 
monomers are induced to dimerize, allowing for the autophosphorylation of multiple 
tyrosine residues within the RET intracellular tyrosine kinase domain, which initiates the 
association of adaptor proteins and enzymes that trigger multiple second messenger 
cascades (Airaksinen and Saarma, 2002). 
Experiments conducted in knockout mouse models have helped identify the 
functions of the GFLs, GFRαs and RET in the developing embryo, including crucial 
roles for RET in kidney development, spermatogenesis and development of the nervous 
system.  In the renal system, RET is required for early induction of growth, branching 
and morphogenesis of the ureteric bud in the developing metanephric kidney 
(Schuchardt et al., 1994, Schuchardt et al., 1996, Vega et al., 1996, Chi et al., 2009, 
Davis et al., 2014). In the testis, RET is responsible for the maintenance and self-
renewal of spermatogonial stem cells and for the regulation of germ cell differentiation 
process in testes (Meng et al., 2000, Naughton et al., 2006, Jijiwa et al., 2008). In the 
nervous system, RET signaling is critical for the development of sympathetic (Enomoto 
et al., 2001), motor (Gould et al., 2008), and sensory nervous systems (Luo et al., 2009, 
Golden et al., 2010), for the development and maintenance of the enteric nervous 
system (Schuchardt et al., 1994, Schuchardt et al., 1996), and also for the postnatal 
maintenance of dopaminergic midbrain neurons (Kramer et al., 2007). 
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Figure 1.1: RET is a receptor for the glial cell line-derived neurotrophic factor 
(GDNF) family ligands (GFLs). (A) The GFLs, GDNF, neurturin (NRTN), artemin 
(ARTN) and persephin (PSPN) are dimerized ligands that first bind to their respective 
GPI-anchored coreceptors, the GDNF Family Receptor-α (GFRα).  (B) GFL-GFRα 
binding to the extracellular domain of RET leads to its dimerization and activation via 
autophosphorylation of the intracellular tyrosine kinase domain.  Figure adopted from 
(Mulligan, 2014). 
B A 
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RET encodes two major protein isoforms that have biologically distinct functions 
The central dogma of molecular biology, established by Francis Crick in 1956, 
describes the flow of genetic information, wherein DNA is transcribed to RNA, which is 
then processed and translated to protein. One of the most interesting and complicated 
steps in this progression is the regulated post-transcriptional processing of RNA in the 
nucleus. When DNA is first transcribed into RNA, the resulting ribonucleic acid is 
comprised of protein-coding exonic sequences as well as non-coding intronic 
sequences, and is referred to as pre-mRNA. The cell uses a complex of small nuclear 
RNAs and proteins, known as the spliceosome, to remove or “splice out” the intronic 
sequences, and then joins together the protein-coding sequences into one continuous 
mRNA transcript that can be translated by the ribosome (Clancy, 2008).   
It was discovered that during the processing of pre-mRNA, the splicing 
machinery pieces together the exonic sequences in different ways such that multiple 
mRNA transcripts can be generated from a single gene (Lee and Rio, 2015). For 
example, in certain tissues an exon can be included to encode one protein product, but 
in another tissue, the exon can be excluded to encode a similar, yet different protein. 
This process has been termed “alternative splicing,” and is now appreciated as one of 
many processes that mediate gene regulation in metazoans, allowing for the generation 
of numerous transcripts from a single protein-coding gene that creates proteomic 
diversity without expanding the genome. Interestingly, the frequency of alternative 
splicing increases with species complexity; Of the approximately 25,000 genes encoded 
by the human genome, ~95% produce transcripts that are alternatively spliced (Wang et 
al., 2008, Pan et al., 2008).  With such an enormous increase in complexity comes an 
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increased susceptibility to malfunction, and defects in pre-mRNA splicing processes 
have emerged as a common disease-causing mechanism (Lee and Rio, 2015).  
By expanding the proteome through the synthesis of various protein isoforms, 
alternative splicing allows for increased protein diversity, with isoforms performing 
selective biological functions by differing in their protein-protein interactions, cellular 
localization and/or catalytic ability. One example of this is fibroblast growth factor 
receptors (FGFRs). FGFRs are a subfamily of four RTKs that are receptors for fibroblast 
growth factors (FGFs), of which there are 18 ligands (Turner and Grose, 2010). 
Alternative splicing of the FGFRs in the region coding for the extracellular ligand-binding 
domain of the receptors allows for differential ligand binding, and thus, differential 
signaling events (Turner and Grose, 2010). Additionally, several neurotrophic factor 
receptors encode multiple isoforms, such as TrkB. One trkB transcript produces a 
truncated form of the receptor, TrkB.T1, that lacks catalytic activity and acts as a 
dominant negative receptor that can inhibit TrkB signaling (Eide et al., 1996). This 
truncated form sequesters and translocates its ligand, brain-derived neurotrophic factor 
(BDNF), and can induce filopodia and neurite outgrowth, stimulate intracellular signaling 
cascades and modify cytoskeletal structures (Fenner, 2012). Additionally, upregulation 
of this truncated TrkB isoform specifically in male mice leads to a loss of sensory 
innervation in mammary glands during development (Liu et al., 2012).   
 RET consists of 20 exons, and encodes two major protein isoforms and one 
minor isoform, all of which are generated from alternative 3’ splicing. These isoforms 
are named for the number of unique amino acids found at the C-terminus of each 
protein; either 9, 43 or 51 (Myers et al., 1995). The two major isoforms, RET9 and 
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RET51, are highly conserved among vertebrates, and a third isoform, RET43, has been 
identified in humans, but has not been found to be conserved in other species (Lee et 
al., 2003). 
Although RET9 and RET51 only differ in their C-termini, these proteins have 
distinct physiological functions and have unique adaptor protein interactions, leading to 
separate signaling abilities (Tsui-Pierchala et al., 2002). For example, mice lacking 
RET9 have renal malformations, defects in enteric nervous system innervation and die 
shortly after birth similar to Ret null mice (de Graaff et al., 2001). However, mice lacking 
RET51 appear normal and survive into adulthood (de Graaff et al., 2001). Additionally, 
there are differences in expression of the two isoforms, both within tissues and during 
developmental times, such as in the kidneys (Ivanchuk et al., 1998). Mice lacking RET9 
have renal malformations due to the early expression of RET9 in development of the 
kidney during branching of the ureteric bud (Ivanchuk et al., 1998). RET51 expression 
increases later in renal development, and likely has a differentiating role rather than a 
mitogenic role in early kidney induction like RET9 (Ivanchuk et al., 1998).  
The two RET isoforms are also regulated in different ways. For example, in the 
sympathetic neurons of the superior cervical ganglion (SCG) where RET51 is more 
highly expressed, Cbl E3 ubiquitin ligase binds to this isoform and rapidly degrades the 
protein via the proteasome (Tsui-Pierchala et al., 2002, Scott et al., 2005). RET9, on the 
other hand, is not degraded nearly as rapidly in the SCG. This is largely due to both the 
absence of a key tyrosine residue in the alternatively spliced C-terminal tail that acts as 
a docking site for the adapter molecules necessary for its degradation, as well as for 
RET translocation into lipid rafts upon activation, which sequesters it from the 
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degradation machinery (Pierchala et al., 2006). However, in sensory neurons of the 
DRG, the GDNF-GFRα1-RET complex is not degraded and is instead retrogradely 
transported to the cell body to support neuron survival and maintenance (Tsui and 
Pierchala, 2010). Taken together, 3’-splicing of Ret to produce RET9 and RET51 
isoforms serves to increase the diversity of the possible signaling capacities of the 
GFLs. 
 
Structure of the RET extracellular and kinase domains and associated 
intracellular signaling pathways 
Since the discovery of RET, numerous experiments have investigated the overall 
structure of the RET protein and how it interacts with the GFLs and GFRαs. A major 
driving force for this is due to the fact that mutations which cause overexpression of 
RET, and therefore, increased signaling, or mutations that cause constitutive activation 
of the RET receptor, are found in a number of cancers (Mulligan, 2014).  It has been 
extremely important to characterize the structure, especially of the intracellular kinase 
domain, to aid in the creation of small molecule inhibitors to treat these cancers. 
Additionally, understanding the overall structure of the protein is important for 
understanding why certain mutations lead to gain-of-function or loss-of-function 
phenotypes. 
As previously stated, the gene encoding RET is 20 exons long.  Exons 1-10 of 
the gene encode the extracellular region of the protein, which is the least conserved 
region between vertebrates, with 40% amino acid sequence identity among vertebrates, 
and 30% amino acid sequence identity after including D. melanogaster Ret (Kjaer et al., 
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2010). Exon 11 encodes the transmembrane domain of the receptor, and exons 12-20 
encode the intracellular domain. Conservation analysis has shown that the cytoplasmic 
kinase domain is the most highly conserved region of the protein, with 90% amino acid 
sequence identity among several vertebrate species. When adding the D. melanogaster 
Ret amino acid sequence to this comparison, the conservation of the kinase domain 
decreases to 65% (Kjaer et al., 2010). 
 
The extracellular domain of RET 
The extracellular domain is comprised of four cadherin-like repeats (CLD1-4) 
(human amino acid sequence, residues 29-516) followed by a membrane-proximal 
cysteine-rich domain (CRD) (residues 517-635) (Anders et al., 2001). The CLDs are 
structurally similar to the extracellular cadherin (EC) domains of cadherin proteins. The 
EC domains of cadherins are important for mediating cell-cell contact and adhesion at 
adherens junctions (Shapiro and Weis, 2009).  RET CLDs, in contrast, do not function in 
this manner and instead function to stabilize the overall structure of the RET dimer. EC 
domains are characterized by a repeating amino acid sequence of approximately 110 
residues with a calcium-binding domain positioned between each EC domain, and 
calcium binding is structurally important for the proper orientation and binding of 
cadherin ectodomains (Shapiro and Weis, 2009).  The RET CLDs are also 
approximately 110 residues in size, but only contain one calcium-binding domain that is 
located between CLD2 and CLD3.  While the loss of the calcium binding domains 
between CLD1-2 and CLD3-4 is thought to allow for increased flexibility of RET in 
binding to GFL-GFRα binary complexes, calcium binding between CLD2-3 is still crucial 
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for the proper folding, secretion and signaling functions of RET (Anders et al., 2001, 
Nozaki et al., 1997, Kjaer et al., 2010). 
 The membrane-proximal CRD is necessary for proper protein conformation as 
well as binding to ligand. Initial mutagenesis experiments argued that the binding of the 
GFL-GFRα binary complex occurs in CLDs1-3; however this interaction was not 
observed in cross-linking experiments (Amoresano et al., 2005, Kjaer and Ibanez, 
2003). Instead the CLD4 and CRD domains of RET are required for the binding of RET 
to the GDNF-GFRα1 binary complex (Amoresano et al., 2005).   
 Understanding the three-dimensional structure of the RET extracellular domain 
has been lacking mainly due to the inability to obtain a full crystal structure. However, 
Kjaer et al. did determine the crystal structure of a CLD1 and CLD2 fragment, which has 
a “clam-shell” shaped structure that forms a secondary dimer between two RET 
monomers following ligand-dependent dimerization (Kjaer et al., 2010). The authors 
proposed a tentative GFL-GFRα-RET ternary complex model in which CLD4 and the 
CRD domains of two RET monomers directly interact with the GLF-GFRα binary 
structure. Upon associating, the membrane-distal CLD1-CLD2 regions of the two RET 
monomers form a clam-shell shaped secondary dimer that helps topologically trap and 
stabilize the GFL-GFRα binary complex (Kjaer et al., 2010). While this predicted model 
has yet to be disproven, additional experiments are still needed to confirm these results. 
 
The RET intracellular domain and signal transduction 
Across the plasma membrane lies the intracellular domain of RET which is 
comprised of a tyrosine kinase domain (residues 724-1016) and a C-terminal tail. As 
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discussed previously, upon GFL-GFRα binding, two RET monomers dimerize, allowing 
for autophosphorylation of multiple tyrosine residues within the kinase domain. This 
causes recruitment of adaptor proteins that bind to the phosphorylated residues and 
themselves become tyrosine phosphorylated by RET. This induces their activation, 
triggering cascades that lead to the activation of multiple downstream signaling 
pathways (Airaksinen and Saarma, 2002). While the activation of these pathways has 
been thoroughly studied, it is worth noting that because RET was an orphan receptor for 
a decade, a great deal of the information regarding RET signal transduction is a result 
of experiments performed with chimeric and/or oncogenic forms of RET (Arighi et al., 
2005). 
The three main signal transduction pathways downstream of RET activation are 
the RAS-MAPK (mitogen activated protein kinase) pathway, the PI3K-AKT pathway and 
the PKC (protein kinase C) pathway (Arighi et al., 2005, Mulligan, 2014). Activation of 
the RAS-MAPK pathway promotes growth and differentiation of neurons (Grimm et al., 
2001). Adaptor proteins, such as GRB2, bind to phosphorylated tyrosine residues of 
RET, which in turn phosphorylates the adaptor protein, allowing further recruitment of 
signaling molecules (Airaksinen and Saarma, 2002). In the RAS-MAPK pathway, these 
adaptor proteins are linked to a guanine nucleotide exchange factor (GEF), such as 
SOS, that transduces the signal to a small GTP binding protein, such as RAS (Mulligan, 
2014).  This in turn activates the main core of this serine-threonine kinase cascade by 
phosphorylating and activating MAPKKK (Raf), which phosphorylates and activates 
MAPKK (MEK1/2), which then phosphorylates and activates MAPK (ERK) (Lodish et al., 
2008). MAPK can then interact with targets in the cytosol, or it can translocate to the 
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nucleus and phosphorylate a variety of transcription factors, which ultimately regulates 
gene expression (Lodish et al., 2008). 
The PI3K-AKT pathway regulates growth, proliferation, survival, transcription and 
protein synthesis within cells (Hemmings and Restuccia, 2012). Upon GFL-GFRα 
binding to RET, adaptor proteins again bind to phosphorylated tyrosine residues in the 
intracellular domain of RET. These adaptor proteins then activate phosphoinositide-3-
kinase (PI3K), which then converts phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids 
to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Hemmings and Restuccia, 2012). 
PIP3 binds to protein kinase B (PKB), also known as AKT, thus recruiting it to the 
plasma membrane where it is phosphorylated and activated by PDK1/2 (Pitt and Chen, 
2008). AKT is a serine/threonine kinase that has numerous cytoplasmic substrates 
(Lodish et al., 2008). Downstream targets of activated AKT include the TSC1/TSC2 
complex, which is part of the mTORC-signaling pathway that regulates protein synthesis 
and cell proliferation (Lodish et al., 2008). Additionally, activated AKT can also promote 
cell survival by inhibiting the function of pro-apoptotic proteins (Pitt and Chen, 2008). 
Lastly, the PKC pathway regulates cell proliferation, differentiation, survival and 
motility (Kang, 2014). Phospholipase C (PLCγ) is recruited to RET and becomes 
activated (Ibanez, 2013). PLCγ produces diacylglycerol (DAG), a lipid second 
messenger, which binds and activates PKC (Kang, 2014). The downstream signaling 
that follows activation of PKC is complex due to the PKCs being a large family of 
isozymes that are diverse in their mechanisms of activation, although all PKCs do 
phosphorylate serine and threonine residues on a large number of downstream 
signaling proteins (Kang, 2014). 
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Within the intracellular domain of RET, the shorter RET9 isoform contains 16 
tyrosine residues, while the RET51 isoform contains 18. Of these many tyrosine 
residues, adaptor proteins have been identified that bind to eight of these tyrosine 
residues; the five most widely studied are Tyr905, Tyr981, Tyr1015, Tyr1062, which are 
located in the kinase domain, and Tyr1096 which is only present in the C-terminal tail of 
the RET51 isoform (Ibanez, 2013). Tyr905, which is a binding site for GRB7 and GRB10 
and signals via the RAS-MAPK pathway, is also an autocatalytic tyrosine that is 
conserved in many RTKs and helps to stabilize the active conformation of the kinase 
(Pandey et al., 1995, Pandey et al., 1996). Mutation of Tyr905 to phenylalanine (Y905F) 
impairs the kinase activity of RET (Iwashita et al., 1996). Tyr981 is a site for SRC 
binding that signals via the PI3K-AKT pathway (Encinas et al., 2001).  Translocation of 
RET into lipid rafts promotes the interaction of SRC with activated RET and enhances 
mitogenesis and neuronal survival (Encinas et al., 2001). Tyr1015 is a docking site for 
PLCγ, which activates the PKC signaling pathway and is crucial for kidney 
morphogenesis and migration of neuro-progenitors in the developing brain (Jain et al., 
2006, Borrello et al., 1996, Lundgren and et al., 2012). Tyr1062 is a multifunctional 
binding site for SHC, Dok4/5, IRS-1, and FRS-2 when phosphorylated and is a binding 
site for Enigma in a phosphorylation-independent manner (Durick et al., 1996, Lorenzo 
et al., 1997, Asai et al., 1996, Arighi et al., 1997, Grimm et al., 2001, Hayashi et al., 
2000, Kurokawa et al., 2001, Melillo et al., 2001b, Melillo et al., 2001a). Interactions 
between Tyr1062 and these adaptor proteins lead to activation of both the RAS-MAPK 
and PI3K/AKT pathways (Asai et al., 1996, Arighi et al., 1997, Besset et al., 2000, 
Kurokawa et al., 2001, Melillo et al., 2001b). Lastly, Tyr1096 is a binding site for GRB2, 
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which signals through the PI3K-AKT signaling pathway, but it can also recruit the CBL 
family of ubiquitin ligases that function in the downregulation of RET51 by initiating 
ubiquitination and degradation (Alberti et al., 1998, Scott et al., 2005, Tsui and 
Pierchala, 2008). Although many of the pathways through which RET transduces 
signals have been identified, far less is known about the target genes that are 
specifically modulated in response to receptor activation. 
   
Role of RET in disease 
Receptor tyrosine kinases play very important roles throughout development, and 
as such, loss or gain of function mutations in these receptors or other proteins in the 
signaling pathway can have deleterious affects on the organism. RET is no exception to 
this rule.  Loss of function mutations in RET are responsible for renal agenesis as well 
as Hirschsprung’s disease, a complex genetic disorder characterized by aganglionosis 
of variable length of the distal gastrointestinal tract (Fig. 1.2) (Mulligan, 2014). This is 
not surprising given the importance of RET signal transduction during development, 
especially in the kidneys and enteric nervous system. On the other hand, gain of 
function mutations in RET play roles in cancer, including the formation of medullary 
thyroid carcinomas and pheochromocytomas, and mutations in RET are also causal for 
Multiple Endocrine Neoplasia Types 2A and 2B (Fig. 1.2) (Mulligan, 2014). 
 
Hirschsprung’s Disease 
In 1888, Harald Hirschsprung first described a condition in infants in which 
patients presented with the absence of spontaneous bowel movements, leading to 
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Figure 1.2: Loss-of-function or gain-of function mutations in the RET signaling 
pathway cause defects in mice.  (A, B) Loss of enteric nervous system innervation 
of the small and large intestine in mice that lack the ability to translocate RET into 
lipid rafts for proper signaling.  Visualization of the myenteric plexes was performed 
using acetylcholinesterase immunohistochemistry in E18.5 wildtype (A) or mutant 
(B) mice.  Figure adopted from (Tsui et al., 2015).  (C, D) Examples of medullary 
thyroid carcinomas (MTC) from mice harboring an activating mutation of RET, 
Cys634Arg, that causes ligand-independent dimerization of RET monomers.  
Thyroid glands from wildtype littermates are on the left of each picture, while thyroid 
glands exhibiting MTC from mutant mice are pictured on the right. (C) Transgenic 
mice backcrossed into CBA/ca genetic background.  (D) Transgenic mice 
backcrossed into FVB/N genetic background.  Figure adopted from (Cranston and 
Ponder, 2003)  	  
A 
B 
C  D 
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intestinal obstruction and chronic constipation (Hirschsprung, 1888). It was later 
discovered that these symptoms resulted from the absence of the enteric nervous 
system due to the failure of neural crest cells to migrate, proliferate, differentiate and/or 
survive in the bowel wall (Obermayr et al., 2013). This condition has since been termed 
Hirschsprung’s Disease (HSCR) or congenital intestinal aganglionosis, and affects 1 in 
every 5000 live births (Bodian and Carter, 1963).  
Colonization of the gut by enteric neural crest-derived cells (ENCCs) is regulated 
by several local signals produced in the gut, and mutations in several of these genes 
have been associated with HSCR, including loss of function mutations in RET 
(Obermayr et al., 2013). Studies in animal models have shown that RET plays an 
essential role in the survival, proliferation, migration and differentiation of ENCCs 
(Heanue and Pachnis, 2007, Laranjeira and Pachnis, 2009). Interestingly, 
approximately half of familial cases of HSCR are associated with loss of function 
mutations in the RET gene (Angrist et al., 1995, Attie et al., 1995). Additionally, 
mutations in GDNF and NRTN have also been described in patients with HSCR, and 
mice haploinsufficient for Gdnf present with Hirschprung-like symptoms including 
intestinal obstruction and early-onset lethality (Parisi and Kapur, 2000, Shen et al., 
2002). 
While the pathogenic role of RET in HSCR has been widely studied, mutations in 
other genes and pathways have been identified as well. The endothelin type B receptor 
pathway has been associated with HSCR, including mutations in EDNRB and EDN3 
that inhibit neuronal differentiation (Obermayr et al., 2013). Interestingly, EDNRB was 
first associated with HSCR because it was linked to the same region of the 
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chromosome as the susceptibility to Hirschsprung Disease 2 locus (Puffenberger et al., 
1994). Additional mutations in genes encoding transcription factors, such as Hoxb5, 
Sox10 and Phox2B, have also been found to be associated with HSCR (Obermayr et 
al., 2013). Unlike RET, however, mutations at other individual loci are not sufficient or 
necessary to cause clinical disease. It is very likely that polymorphisms at several loci 
contribute in a combinatorial manner to cause this complex genetic disorder.  
 
Multiple endocrine neoplasia, type 2 
RET gain-of-function mutations that lead to over-activation of the receptor arise 
from missense changes that induce constitutive activation of the receptor, or its aberrant 
over-expression, allowing for ligand-independent receptor activation (Mulligan, 2014). 
This increase in signaling via RET is associated with several familial and sporadic 
cancers of neuroendocrine organs. In the autosomal dominantly inherited syndrome 
multiple endocrine neoplasia type 2 (MEN2), numerous causal mutations have been 
identified within the RET gene (Arighi et al., 2005). The syndrome, which affects one in 
every 35,000 individuals, is characterized by the presence of multiple endocrine tumors 
including a form of thyroid cancer known as medullary thyroid carcinoma (MTC), tumors 
of the adrenal gland known as pheochromocytomas, as well as benign tumors of the 
parathyroid glands known as parathyroid adenomas (Mulligan, 2014).  
MEN2 is subdivided into three categories based upon the neoplasms of the 
patient and includes familial medullary thyroid carcinoma (FMTC), MEN2A and MEN2B.  
Patients who present primarily with MTC are classified as having FMTC. MEN2A is 
characterized by MTC and includes pheochromocytomas in 50% of cases and also 
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parathyroid adenomas. MEN2B is the most severe disease phenotype, and has the 
earliest onset and poorest survival of the MEN2 subtypes (Mulligan, 2014). MEN2B is 
characterized by MTC and pheochromocytomas, as well as other developmental 
anomalies that are consistent with RET function in embryonic development (Arighi et al., 
2005).  
The MEN2 mutations that arise in RET are generally single amino acid 
substitutions that fall in one of two regions of the receptor and ultimately lead to 
constitutive activation and signaling (Mulligan, 2014). Although numerous casual 
variants have been identified in patients with MEN2, mutations primarily affect the 
extracellular cysteine-rich domain (MEN2A) or the intracellular kinase domain (MEN2B). 
In MEN2A, more than 95% of patients have amino acid substitutions of C609, C611, 
C618, C620, C630 or C634, with mutations at C634 being the most common (Pasini et 
al., 1996). These cysteines, which lie just proximal to the transmembrane domain of 
RET, form disulfide bonds that are required for the proper three-dimensional structure of 
RET (Mulligan, 2014). However, when one of these cysteines is mutated, it leaves one 
of the five remaining cysteines unpaired, allowing it to form intermolecular bonds and 
induce ligand-independent receptor dimerization. Interestingly, amino acid substitutions 
at C609, C611, C618, or C620 are deemed “Janus mutations.” Individuals with 
substitutions at these positions within RET present with both a gain-of-function and a 
loss-of-function phenotype. It was found that this “mixed” phenotype is due to the lack of 
proper maturation of RET proteins, leading to a decrease in RET expression on the cell 
surface (Arighi et al., 2005). As a consequence, some patients have neuroendocrine 
tumors as well as kidney and enteric nervous system abnormalities (Arighi et al., 2005). 
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MEN2B mutations fall in the intracellular kinase domain of RET, and most 
commonly include amino acid substitutions of M918T and M883F (Carlson et al., 1994, 
Smith et al., 1997). These mutations are located near the activation loop of the kinase 
domain, and have been shown to change the conformation of the protein, allowing for 
an increase in the basal kinase activity of the receptor, especially M918T (Santoro et al., 
1995). Additionally, the M918T mutation alters substrate binding by affecting the 
autophosphorylation sites of the receptor as well as the phosphorylation of intracellular 
adaptor proteins (Santoro et al., 1995). 
MTCs and pheochromocytoma tumor samples have been thoroughly analyzed 
for other mutations in RET that could be causal or aid in tumor progression for MEN2.  
During the course of these studies, three novel RET transcripts were identified in 
pheochromocytomas that were the product of exon skipping in the 5’ region of RET, 
which encodes for the extracellular domain of the protein (Lorenzo et al., 1995).  
Skipping of exons 3 (RETΔE3) or exons 3, 4 and 5 (RETΔE345) give rise to transcripts that 
encode for full-length RET proteins, but with deletions in the extracellular domain, 
specifically cadherin-like domain 1 (CLD1), or CLD1-3, respectively. We have 
hypothesized that these deletions change the extracellular domain structure as well as 
binding to GFL-GFRα complexes, and may impact overall stability of the proteins. The 
skipping of exons 3 and 4 (RETΔE34) results in a frameshift that culminates in a 
premature stop.  This protein encodes only a small portion of the RET extracellular 
domain with no transmembrane or intracellular domain (Lorenzo et al., 1995). Because 
this transcript is likely to be subjected to nonsense-mediated decay, it is unlikely to be 
involved in RET signal transduction. However, beyond analyzing the expression of 
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these transcripts, expression of these potential isoforms and the functional role they 
may play in disease formation and/or progression has not been elucidated.  
 
The Sympathetic Nervous System as a Model to Study RET Signal Transduction 
and Programmed Cell Death 
 The sympathetic nervous system, part of the autonomic nervous system, is 
responsible for maintaining homeostasis within the body, and is most commonly known 
for controlling the body’s “fight or flight” response. This subset of the nervous system is 
responsible for regulating many physiological processes, including but not limited to 
body temperature, blood pressure, respiration, cardiac output, and blood glucose levels 
(Janig and Habler, 2000). The importance of the sympathetic nervous system can best 
be observed when it becomes dysfunctional, playing roles in hypertension, congestive 
heart failure, dysautonomia, and various neuropathies (Glebova and Ginty, 2005). 
 The sympathetic nervous system consists of paired cholinergic preganglionic 
sympathetic neurons whose cell bodies reside in the intermediolateral horn of the spinal 
cord. These neurons make synaptic connections with post-ganglionic, predominantly 
noradrenergic sympathetic neurons that are situated as paired ganglia that run the 
length of the body on either side of the spinal cord. These post-ganglionic neurons 
project their axons to many different target tissues and glands (Figure 1.3). The anterior 
most pair of ganglia are the superior cervical ganglia (SCG), which innervate a number 
of targets within the head as well as the heart and trachea. These ganglia have been 
used extensively to study both RET signal transduction and programmed cell death 
(Glebova and Ginty, 2005).   
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Figure 1.3: Schematic representation of the sympathetic nervous system in the 
mouse. Preganglionic sympathetic neurons (green) are located in the 
intermediolateral column (IML) at thoracic and lumbar levels of the spinal cord.  
These cholinergic preganglionic neurons make synaptic connections with post-
ganglionic sympathetic neurons (yellow), which include the paravertebral ganglia 
consisting of the superior cervical ganglion (SCG), the stellate ganglion (SG) and the 
sympathetic chain (SC), and prevertebral ganglia, including the celiac ganglion (CG), 
the superior mesenteric ganglion (SMG), and the inferior mesenteric ganglion (IMG).  
The post-ganglionic sympathetic neurons project their axons (blue) to many different 
target tissues and glands.  Figure adopted from (Glebova and Ginty, 2005). 	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RET plays several roles throughout SCG development. In Ret-/- mice, the SCG is 
mislocated, failing to correctly migrate to its proper rostal position (Enomoto et al., 
2001). Additionally, sympathetic neuronal precursors display severe deficits in axonal 
projections, leading to a dramatic loss of target innervation (Enomoto et al., 2001). 
These developmental events are dependent on the proper signaling of 
ARTN/GFRα3/RET (Nishino et al., 1999, Honma et al., 2002). 
In vitro models in which SCGs are isolated, dissociated and maintained as 
primary neuronal cultures have been used to study many aspects of basic RET biology 
including, but not limited to, trafficking within the cell, signal transduction and 
degradation (Tsui-Pierchala et al., 2002, Pierchala et al., 2006, Tsui and Pierchala, 
2010, Calco et al., 2014). Additionally, GDNF and RET can support the survival of 
approximately 30% of neurons in primary sympathetic cultures (Yu et al., 2003). 
The SCG has not only been used as a model to study RET, but it has also been 
used as a model to understand the molecules and underlying mechanisms important for 
programmed cell death.  Development of the nervous system is an immensely 
complicated process, and requires coordination of multiple signaling events to create 
properly functioning circuits. To ensure the correct neural connections are formed, twice 
as many neurons are born than will be needed in adulthood, and those not making 
proper or strong enough connections will be eliminated through a process known as 
programmed cell death (PCD) (Oppenheim, 1991). In the mouse SCG, PCD occurs late 
perinatally through early postnatal stages (~E17-P20) (Bamji et al., 1998), and during 
this time, sympathetic neurons require nerve growth factor (NGF) for their survival (Levi-
Montalcini, 1987). NGF is secreted in limited amounts from target tissues, and binds to 
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the receptor tyrosine kinase, TrkA, located on sympathetic axons (Glebova and Ginty, 
2005). Upon binding, this NGF-TrkA complex is retrogradely trafficked to the cell body 
and promotes neuronal survival and inhibits apoptosis in these “winning” cells (Glebova 
and Ginty, 2005). However, axons that do not reach their target or arrive late to the 
target fail to receive enough NGF to support their survival, and these “losing” neurons 
will die via an intrinsic PCD mechanism (Glebova and Ginty, 2005, Conradt, 2009). 
PCD in the SCG is complicated by the presence of the p75 neurotrophin receptor 
(p75NTR, NGFR, TNFRSF16). p75 is a promiscuous receptor, binding to TrkA and 
enhancing its survival signaling (Verdi et al., 1994, Barker and Shooter, 1994). 
However, in the absence of Trk receptors, p75 can function as a lower affinity receptor 
for members of the neurotrophin family, and signaling in this context can upregulate cell 
death-signaling pathways (Bamji et al., 1998, Aloyz et al., 1998). During PCD, “winning” 
neurons take advantage of this by releasing “competition factors” such as brain-derived 
neurotrophic factor (BDNF) that binds to p75 (Deppmann et al., 2008, Teng et al., 
2010). The “winning” neurons that receive sufficient survival signals through NGF-
TrkA/p75 signaling are protected from the competition factor, but the “losing” neurons 
are vulnerable to these cues and will die via an extrinsic BDNF-p75 mediated PCD 
mechanism (Bamji et al., 1998, Deppmann et al., 2008). 
Interestingly, RET is expressed in a small subset of neurons in the SCG during 
this period of PCD in vivo, but its role during this time has not been elucidated.  
Experiments by Enomoto et al. demonstrated that RET is not required for the survival of 
these neurons during this time (Enomoto et al., 2001), leaving unanswered the question 
about the role of RET during this developmental time. 
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Unanswered questions in the field 
Discovering how a cell manages the activity, abundance, cellular distribution and 
turnover of RTKs is essential to understanding the phenotypes that occur when these 
activities are dysregulated in pathophysiological conditions. For RET, factors have been 
identified that modulate transcription of the receptor, such as the DNA binding factors 
SPI, SP3 and EGR1, and additional factors that contribute to the tissue-specific 
expression of RET during development, such as SOX10, Phox2b and Pax3 (Andrew 
and et al., 2002, Leon and et al., 2009). Additionally, alternative splicing of the 3’ region 
of RET, encoding the C-terminal tail, has allowed for different mechanisms of signal 
transduction, as well as the differential regulation of trafficking and turnover of the 
protein. Although much has been done to understand the biology and pathobiology of 
RET, there is still a need to better understand mechanisms of modulation of its signal 
transduction pathways.     
Beyond the three isoforms that have been reported, additional transcripts have 
been observed in human pheochromocytomas that arise from alternative splicing in the 
5’ region of RET, as previously mentioned (Lorenzo et al., 1995). Interestingly, RETΔE3 
and RETΔE345 transcripts are also present in normal kidney and brain tissues, but at 
much lower expression levels (Lorenzo et al., 1995). It is unknown whether these 
transcripts are translated to protein, if they interact with GLF-GFRα complexes in a 
ligand dependent manner, and what their potential biological and pathobiological 
functions may be. I explore these questions in Chapter 2. 
 Interestingly, p75 interacts with a number of receptors and thereby modulates 
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their activity and function. For example, p75 interacts with the receptor tyrosine kinase, 
TrkA, and increases the affinity of the NGF/TrkA interaction, thus enhancing pro-survival 
and pro-growth signaling (Davies et al., 1993). Preliminary data suggest that p75 
interacts with RET and functions to enhance the differentiation and maintenance of non-
peptidergic nociceptors in the dorsal root ganglion during development (Chris Donnelly, 
Kuo Fen Lee, unpublished data). However, we have found that pro-apoptotic signals 
can induce the association of p75 and RET in the sympathetic nervous system.  
Surprisingly, RET forgoes its pro-growth and pro-survival signaling to enhance the 
function of p75-mediated cell death, which is the first time that an RTK has been shown 
to enhance the functions of TNF-receptor cell death signaling pathways.  In Chapter 3, I 
explore the interactions of p75 and RET both in vitro and in vivo, and investigate the 
role these proteins play during programmed cell death in the sympathetic nervous 
system. The implications of the results in Chapters 2 and 3 for neural development and 
pathophysiology of neuroendocrine tissues will be discussed in Chapter 4. 
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CHAPTER 2 
 
EXON SKIPPING IN RET ENCODES NOVEL ISOFORMS THAT DIFFERENTIALLY 
REGULATE RET SIGNAL TRANSDUCTION 
 
 
Summary 
RET, a receptor tyrosine kinase that is activated by the glial cell line-derived 
neurotrophic factor (GDNF) family ligands (GFLs), plays a crucial role in the 
development and function of the nervous system, and additionally is required for kidney 
development and spermatogenesis.  RET encodes a transmembrane receptor that is 20 
exons long and produces two known protein isoforms differing in C-terminal amino acid 
composition, referred to as RET9 and RET51.  Studies of human pheochromocytomas 
identified two additional novel transcripts involving the skipping of exon 3 or exons 3, 4, 
and 5 and are referred to as RETΔE3 and RETΔE345, respectively. Here we report the 
presence of RetΔE3 and RetΔE345 in zebrafish, mice, and rats, and show that these 
transcripts are dynamically expressed throughout development of the CNS, PNS and 
kidneys. We further explore the biochemical properties of these isoforms, demonstrating 
that, like full-length RET, RET∆E3 and RET∆E345 are trafficked to the cell surface, interact 
with all four GFRα co-receptors, and have the ability to heterodimerize with full-length 
RET. Signaling experiments indicate that RETΔE3 is phosphorylated in a similar manner 
to full-length RET. RETΔE345, in contrast, displays higher baseline autophosphorylation, 
specifically on the catalytic tyrosine, Tyr905, and also on one of the most important 
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signaling residues, Tyr1062. These data provide the first evidence for a physiologic role 
of these isoforms in RET pathway function. 
 
Introduction 
RET is a receptor tyrosine kinase that is critical for kidney morphogenesis, 
spermatogenesis, and development of the nervous system (Airaksinen and Saarma, 
2002, Baloh et al., 2000, Meng et al., 2000, Naughton et al., 2006). RET is activated by 
a family of four growth factors known as the glial cell line-derived neurotrophic factor 
(GDNF) family ligands (GFLs), which includes GDNF, neurturin (NRTN), artemin 
(ARTN), and persephin (PSPN) (Airaksinen and Saarma, 2002).  Each GFL binds to 
one of four cognate glycosylphosphatidylinositol (GPI) anchored co-receptors known as 
the GDNF Family Receptor-αs (GFRαs) (Airaksinen et al., 1999, Baloh et al., 2000).  
The GFL-GFRα complex binds to RET, inducing RET dimerization and subsequent 
autophosphorylation on multiple tyrosine residues within the intracellular tyrosine kinase 
domain.  This enhances tyrosine kinase activity and initiates the association of adaptor 
proteins and enzymes that trigger multiple second messenger cascades (Wells, 2009). 
The presence of two major Ret isoforms, RET9 and RET51, has been 
extensively described in the literature, and a third isoform, RET43 has also been 
observed in humans (de Graaff et al., 2001, Carter et al., 2001, Tahira et al., 1990).  Ret 
is 20 exons long, and Ret9 and Ret51 transcripts differ in alternative splicing of intron 
19.  Intron 19 in the Ret51 transcript is excised properly, whereas in the Ret9 transcript, 
the intron is retained, changing the reading frame and inserting a premature stop codon 
into the amino acid sequence.  This creates a unique 9 amino acid C-terminal sequence 
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for RET9 and a unique 51 amino acid C-terminal sequence for RET51.  Interestingly, 
these two different isoforms display marked differences in their degradation and function 
(de Graaff et al., 2001, Tsui-Pierchala et al., 2002b, Tsui and Pierchala, 2010).  
Three additional Ret transcripts have been reported in various tumor sources as 
well as adult human tissues (Lorenzo et al., 1995).  These novel transcripts are a 
product of exon skipping in the 5’ region of RET, which encodes for the extracellular 
domain of the protein.  Skipping of exons 3 (RETΔE3) or exons 3, 4 and 5 (RETΔE345) 
gives rise to transcripts that encode for full-length Ret proteins, but with deletions in the 
extracellular domain, specifically cadherin-like domain 1 (CLD1), or CLD1-3, 
respectively.  These deletions are hypothesized to change the extracellular domain 
structure as well as binding to GFL-GFRα complexes, and may impact overall stability 
of the proteins.  The skipping of exons 3 and 4 results in a frameshift that culminates in 
a premature stop.  This protein encodes only a small portion of the RET extracellular 
domain with no transmembrane or intracellular domain.  Because this transcript is likely 
to be subjected to nonsense-mediated decay, it is unlikely to be involved in RET signal 
transduction.  
Here we show that RetΔE3 and RetΔE345 transcripts are conserved in vertebrates, 
and that the mRNA and proteins of these splice variants are expressed throughout the 
nervous system in mice.  We also show that these isoforms are trafficked to the cell 
surface and that both isoforms interact with all four GFRαs.  Additionally, we find that 
RETΔE3 is phosphorylated to a similar level as full-length RET. However, RETΔE345 
displays higher baseline autophosphorylation, specifically on the catalytic tyrosine, 
Tyr905, and also on an additional signaling tyrosine, Tyr1062. Taken together, these 
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isoforms may have unique and important unidentified roles in the development and 
maintenance of the nervous system and kidneys, as well as in the pathophysiology of 
neuroendocrine gland diseases. 
 
Results 
Exons 3, 4, and 5 of Ret are not highly conserved, but RETΔE3 and RETΔE345 
transcripts are observed in several organisms. 
It has been previously described that the intracellular domain of RET, which 
contains a tyrosine kinase domain, is more highly conserved than the extracellular 
domain (Anders et al., 2001). To better understand the level of conservation of amino 
acids encoded by each exon, we compared sequences from zebrafish (Danio rerio), 
mouse (Mus musculus), rat (Rattus norvegicus), and humans (Homo sapiens).  We 
found that the entire intracellular domain was more than 75% conserved at the amino 
acid level.  This was not surprising since mutations in many of these highly conserved 
regions give rise to loss of function (e.g. Hirschsprung’s disease) or gain of function 
(e.g. multiple endocrine neoplasia type 2A and 2B) phenotypes (Fig. 2.1A).  
Interestingly, exons 3, 4 and 5 are less than 50% conserved between these species.  
While this lack of conservation is suggestive that these regions of RET are not as 
functionally important, it could also be interpreted as allowing for amino acid flexibility 
between the different RET isoforms. 
Our initial sequence analysis suggested that RETΔE3 and RETΔE345 transcripts 
could be expressed in additional vertebrates other than homo sapiens.  These 
transcripts were originally identified in human kidney and substantia nigra fetal tissues 
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(Lorenzo et al., 1995). Sequence analysis demonstrated that exon skipping also 
encodes potential full-length transcripts in zebrafish, mice and rats (Fig. 2.1A). To 
determine whether these novel transcripts were expressed in these organisms, species 
specific primers were created to identify each of the Ret transcripts: full-length Ret, 
RetΔE3 and RetΔE345. RT-PCR analysis identified the presence of RetΔE3 and RetΔE345 
from 48 hpf zebrafish embryos, E19.5 rat dorsal root ganglia, and E18.5 mouse spinal 
cord (Fig. 2.1B). Sequence analysis confirmed these amplicons to be RetΔE3 and 
RetΔE345 (data not shown). This is the first time these transcripts have been identified in 
vertebrates other than Homo sapiens. Taken together, these data indicate that 5’ exon 
skipping is conserved and results in the expression of RetΔE3 and RetΔE345 transcripts. 
 
Exon skipping creates large deletions in the extracellular domain of RET. 
To understand the impact deletions in the extracellular domain would have on 
RET, we analyzed the deletions in terms of a CLD1-4 model derived from electron 
microscopy and SAXS analyses (Goodman et al., 2014). The main consequence of 
deletion of exon 3 is the removal of half of CLD1 (residues 113 to 150) and half of CLD2 
(residues 154 to 208). Each domain adopts a β-sandwich cadherin fold comprised of 
two β-sheets, separated by numerous buried hydrophobic residues. Elimination of exon 
3 removes one sheet from CLD1 and a several β-strands from both sheets of CLD2 
(Fig. 2.1C). Therefore, it is likely that both CLD domains are substantially perturbed 
leaving β-strands and exposed hydrophobic residues. Exon 3 removal also eliminates a 
highly constrained Cis-Pro loop (cysteine137-cysteine142) unique to higher vertebrate 
RET sequences. The portion of CLD1-2 removed coincides with regions stabilizing the 
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clam-shell arrangement of CLD1-2 (Kjaer et al., 2010). This would result in a more open 
and extended arrangement for the remaining parts of CLD1 and CLD2 with much 
greater flexibility between the domains. An odd number of cysteine residues (3 in total) 
are deleted by removing exon 3 including the Cys157-Cys197 disulfide. Cys166 is also 
removed leaving its partner Cys243 unpaired but buried. The two unpaired cysteines, 
Cys87 and Cys216, that constitute a known folding bottleneck in wild type RET are left 
untouched.  We expect RETΔE3 to be a less stable, transmembrane protein with a short 
half-life that retains at least some ligand-binding properties. 
For RETΔE345, removal of exons 3, 4 and 5 effectively eliminates much of CLD1-3 
but leaves CLD4-CRD intact (Fig. 2.1C). This region by itself was shown to be 
insufficient to bind ligand but retains at least one important binding epitope (i.e. 
necessary for ligand binding but not sufficient) (Goodman et al., 2014). Many receptor 
tyrosine kinases have extracellular domains that have auto-inhibitory functions in the 
absence of ligand. Deletion of such regions can lead to auto-activation in a ligand-
independent manner. By analogy with these other systems, removal of CLD1-3 could 
leave a truncated form of RET that would be constitutively activated in the absence of 
ligand and likely would be unresponsive to the GFLs. 
 
RetΔE3 and RetΔE345 are co-expressed in several tissues with Ret throughout 
development. 
To determine where and when RetΔE3 and RetΔE345 transcripts are expressed, 
and whether their expression levels change over time, we analyzed tissues in which full 
length Ret is expressed at several developmental time points.  Within the central 
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nervous system, we analyzed the brain, as signaling via Ret is important for the survival 
of central noradrenergic neurons and dopaminergic neurons in the ventral midbrain, as 
well as the spinal cord where GDNF/GFRα1/Ret signaling is critical for axon guidance 
into the hindlimbs and survival of γ-motor neurons (Arenas et al., 1995, Horger et al., 
1998, Bonanomi et al., 2012, Shneider et al., 2009, Gould et al., 2008, Kramer et al., 
2006). In the peripheral nervous system, we analyzed sensory neurons of the dorsal 
root ganglia (DRG) where NRTN/GFRα2/Ret signaling is important for the survival and 
maintenance of mechanoreceptors during development (Luo et al., 2009, Bourane et 
al., 2009).  Additionally, shortly after birth, a subclass of nociceptors transition from 
being TrkA positive to expressing GFRα1/Ret to support the development and survival 
of nonpeptidergic nociceptors (Molliver et al., 1997, Luo et al., 2007, Franck MC, 2011). 
Sympathetic neurons of the superior cervical ganglia (SCG) were also analyzed as it 
has been well established that ARTN/GFRα3/Ret signaling is necessary for proper 
sympathetic chain migration and axon guidance during development (Nishino et al., 
1999, Enomoto et al., 2001, Honma et al., 2002). Lastly, the kidney was analyzed 
because GDNF/GFRα1/Ret signaling is crucial for ureteric bud branching and 
morphogenesis of the kidney (Moore et al., 1996, Pichel et al., 1996, Sanchez et al., 
1996, Cacalano et al., 1998, Enomoto et al., 1998). Using qPCR, we examined the 
relative expression of Ret, RetΔE3 and RetΔE345 in each of these tissues in mice and 
found they were detected in all five tissues.  The relative expression of Ret, RetΔE3 and 
RetΔE345 was lower in brain, spinal cord, and kidney (Fig. 2.2A) compared to the DRG 
and SCG (Fig. 2.2B).  Interestingly, in the spinal cord, DRG and SCG there was a 
significant increase of RetΔE3 expression at E19.5 that preceded a significant increase of 
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Ret at P3.  The expression of all three transcripts was highest in the DRG, particularly at 
E19.5 and P3, when the IB4+ subpopulation of nociceptors is emerging. 
 
5’ and 3’ alternative splicing of Ret transcripts are not mutually exclusive. 
 Alternative splicing of intron 19 in Ret allows for the translation of two isoforms of 
Ret, RET9 and RET51. We sought to determine whether alternative splicing could occur 
simultaneously, both 5’ and 3’ in Ret transcripts, allowing for increased diversity of 
encoded RET proteins.  cDNA was isolated from E19.5 mouse DRGs, as we found this 
tissue to have the highest relative expression of Ret, RetΔE3, and RetΔE345 (Fig. 2.2B). 
Forward primers specific for each 5’ splicing event were paired with reverse primers that 
would detect either Ret9 or Ret51 alternative splicing.  Full-length Ret9 and Ret51 
transcripts were detected, as expected, at 3.33 kb and 4.38 kb, respectively. We 
observed RetΔE3 and RetΔE345 with intron 19 retention, thus encoding Ret9ΔE3 and 
Ret9ΔE345 transcripts with amplicons of 3.05 kb and 2.61 kb.  However, we were only 
able to detect RetΔE345 with a properly excised intron 19 at an amplicon size of 3.66 kb, 
encoding a Ret51ΔE345 transcript.  While we were unable to detect a Ret51ΔE3 transcript 
(4.10 kb), this is likely due to the generally low expression levels of RetΔE3. Taken 
together, these data indicate that the Ret locus encodes for at least three previously 
unidentified transcripts, and at least five total Ret isoforms - Ret9, Ret9ΔE3, Ret9ΔE345, 
Ret51 and Ret51ΔE345. 
 
RETΔE345 proteins are detected in vivo.  
Although we can detect RetΔE3 and RetΔE345 mRNA transcripts, which are likely 
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being processed for translation, we sought to detect the presence of these isoforms at 
the protein level. Plasmids encoding human RET51, RET51ΔE3 and RET51ΔE345 were 
transfected into NIH/3T3 cells, and lysates were run as size standards to aid in 
detecting Ret isoforms of the appropriate molecular weights from E18.5 mouse brain.  
The molecular weight of native RET51 protein is 120 kDa, but due to post-translational 
modifications, specifically glycosylation of the extracellular domain, RET51 has a 
molecular weight of ~180 kDa.  The native molecular weights of RETΔE3 and RETΔE345 
were predicted to be 109 kDa and 93 kDa, respectively.  In transfected cells we 
consistently observe the mature, processed proteins to have molecular weights of ~150 
kDa (RETΔE3) and ~125 kDa (RETΔE345) (Fig. 2.2D).  
Whole brains from Ret+/+ or Ret-/- E18.5 littermate mice were lysed, divided in 
two, and immunoprecipitations were performed to isolate either RET9 or RET51 
proteins.  Although the qPCR data suggested that Ret transcripts have an overall lower 
relative expression in the brain compared to PNS tissues, the brain was chosen for 
analysis because of the abundant amount of protein that could be isolated. Ret-/- mice 
were used as a control to demonstrate specificity of the Ret immunoblotting, and to 
show the presence of RET proteins at the same molecular weight as RETΔE3 and 
RETΔE345.  Since we previously observed more highly expressed Ret9ΔE345 and 
Ret51ΔE345 transcripts compared to those of RetΔE3, we hypothesized that we would be 
most able to detect both RET9ΔE345 and RET51ΔE345 proteins. By immunoblotting for 
RET, we were able to detect full-length RET9 and RET51 proteins, as expected (Fig. 
2.2D). Additionally, we observed RET9 and RET51 bands with similar molecular 
weights to RETΔE345, suggesting the presence of RET9ΔE345 and RET51ΔE345 proteins in 
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mouse brain (Fig. 2.2D). Because the antibody used for immunoprecipitations of RET9 
and RET51 are to the C-terminus, and the RET antibody for immunoblotting is to the 
common N-terminal region, this RET protein is unlikely to be a degradation product.  
However, we cannot exclude the possibility that this is an immature, non-glycosylated 
full-length RET protein. 
 
RETΔE3 and RETΔE345 are trafficked to the cell surface 
To examine the biochemical properties of RETΔE3 and RETΔE345, we transitioned 
to an in vitro system for these experiments.  Although RETΔE3 and RETΔE345 encode 
proteins that may be capable of signaling, this does not guarantee that they will be 
correctly trafficked to the cell surface for activation. To determine if RETΔE3 and 
RETΔE345 are trafficked to the plasma membrane, NIH/3T3 cells were transfected with 
C-terminally epitope tagged Ret constructs that also contain an IRES-GFP to serve as 
an indicator for transfected cells.  Taking advantage of a RET antibody specific for the 
extracellular domain and using a HA antibody to label the C-terminus of RET, we were 
able to selectively visualize RET located on the plasma membrane. Full-length RET was 
detected on the cell surface of transfected NIH/3T3 cells, as expected (Fig. 2.3K).  
Permeabilization revealed the C-terminal HA tag, confirming the integrity of the plasma 
membrane (Fig. 2.3P).  Similar to full-length RET, both RETΔE3 and RETΔE345 were 
trafficked to the cell surface as determined with the extracellular RET antibody in non-
permeabilized cells (Fig. 2.3S, Fig. 2.3A’).  Transfection of GFP alone showed no 
labeling with the RET and HA antibodies, regardless of permeabilization, confirming the 
specificity of our immunostaining (Fig. 2.3A-H).  Thus, RETΔE3 and RETΔE345 are 
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trafficked properly to the cell surface where they can participate in GFL-mediated 
activation. 
 
RETΔE3 and RETΔE345 bind to GFRα1, GFRα2, GFRα3 and GFRα4 
Previous structural analysis (Fig. 2.1C) suggested that interactions between 
RETΔE3 and the GFRαs may be unstable and that RETΔE345 would be unlikely to bind to 
the co-receptors due to deletions of important binding residues in CLD1 and CLD3.  To 
confirm these results, we co-transfected HEK293T cells with RETΔE3 or RETΔE345 and 
HA epitope tagged GFRα constructs.  Immunoprecipitations were performed using a 
stringent immunoprecipitation buffer (modified RIPA buffer) to eliminate any weak, non-
specific interactions.  Surprisingly, we found that both RETΔE3 and RETΔE345 bind to each 
of the four GFRαs (Fig. 2.4).  Co-transfection of the GFRαs with TrkA, another receptor 
tyrosine kinase, was performed as a negative control to show selectivity of binding 
between the GFRαs and RET (Fig. 2.4). As expected, TrkA did not associate with any of 
the GFRαs. There were no apparent differences between the four different GFRαs in 
regard to the extent of their association with RETΔE3 and RETΔE345, suggesting that 
these splice variants could potentially be activated by all four GFLs (Fig. 2.4). 
 
RETΔE3 and RETΔE345 heterodimerize with full-length RET 
In addition to being potential signaling molecules on their own, we observed that 
these transcripts are normally expressed in tissues where full-length RET is also 
expressed (Fig. 2.2).  Although these isoforms may be present in different cells within 
these tissues, these observations raise the question of whether RETΔE3 and RETΔE345 
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could heterodimerize with full-length RET and affect its function.  To test this possibility, 
HEK293T cells were co-transfected with HA epitope tagged RET51 and untagged 
RETΔE3 or RETΔE345.  Immunoprecipitations were performed using a HA antibody to 
select for full-length RET51 and determine if the different isoforms could interact with 
one another (Fig. 2.5A).  In an additional experiment, FLAG tagged RET51ΔE345 (FLAG:: 
RET51ΔE345) was co-transfected with RET51 and RET51ΔE3, and immunoprecipitations 
were performed using a FLAG antibody to select for RET51ΔE345 (Fig. 2.5B).  We found 
that both RET51ΔE3 and RET51ΔE345 associated with full-length RET51, and that 
RET51ΔE3 and RET51ΔE345 could also bind to one another (Fig. 2.5).  This is consistent 
with former experiments suggesting that overexpression of RET proteins allows for 
ligand-independent dimerization via the transmembrane domain (Kjaer et al., 2006). 
 
RETΔE345 has increased ligand-independent activation compared to RET and 
RETΔE3. 
In order to determine levels of activation of RETΔE3 and RETΔE345, the basal 
phosphorylation of tyrosine residues of the splice variants were compared to full-length 
RET phosphorylation. Overexpression of the RET isoforms in vitro, either in the 
presence or absence of a GFRα, allows for ligand-independent dimerization and 
activation of RET.  The level of activation can be assessed by determining the 
summated level of all of the phosphorylated tyrosines using a pan phosphotyrosine 
antibody, or individual tyrosine residues can be analyzed using residue-specific RET 
phosphotyrosine antibodies. We evaluated the level of total phosphotyrosine (P-Tyr) 
between the RET isoforms, as well as individually evaluating phosphorylation at two 
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tyrosine residues of RET, Tyr905 and Tyr1062. Tyrosine 905 in the RET kinase domain 
is an autocatalytic tyrosine that is conserved in many receptor tyrosine kinases (RTKs) 
and is a binding site for GRB7 and GRB10 (Durick et al., 1996, Pandey et al., 1995, 
Pandey et al., 1996).  Additionally, mutation of tyrosine 905 to phenylalanine (Y905F) 
impairs the kinase activity of RET (Iwashita et al., 1996).  Tyrosine 1062 is a binding site 
for SHC, Dok4/5, IRS-1, and FRS-2 when phosphorylated and is a binding site for 
Enigma in a phosphorylation-independent manner (Durick et al., 1996, Lorenzo et al., 
1997, Asai et al., 1996, Arighi et al., 1997, Grimm et al., 2001, Hayashi et al., 2000, 
Kurokawa et al., 2001, Melillo et al., 2001b, Melillo et al., 2001a).  Interaction between 
Tyr1062 and these adaptor proteins leads to activation of Ras/ERK and PI3K/AKT 
pathways (Asai et al., 1996, Arighi et al., 1997, Besset et al., 2000, Kurokawa et al., 
2001, Melillo et al., 2001b). 
To evaluate RET phosphorylation, NIH/3T3 cells were transfected with RET51, 
RET51ΔE3 or RET51ΔE345 constructs in the presence or absence of GFRα1, and the total 
levels of phosphorylated RET, or the level of phosphorylation at Tyr905 and Tyr1062, 
were assessed. To analyze total P-Tyr levels of RET, immunoprecipitations of RET51 
were performed followed by immunoblotting for P-Tyr (Fig. 2.6A).  An increase in the 
level of RETΔE345 phosphorylation compared to full-length RET was observed, but this 
was not statistically significant (p=0.0837).  We did detect, however, a significant 
increase in the P-Tyr level of RETΔE345 co-expressed with GFRα1 compared to full-
length RET co-expressed with GFRα1 (p=0.0366). The phosphorylation of RETΔE3 co-
expressed with GFRα1, or expressed alone, was not significantly different than full-
length Ret (p=0.6231). 
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To determine levels of phospho-Tyr905 and phospho-Tyr1062, pre-IP lysates 
were collected from samples in the previous experiments, and immunoblotting was 
performed using antibodies specific for these two phosphorylated tyrosine residues (Fig. 
2.6B).  Levels of phospho-Tyr905 and phospho-Tyr1062 were significantly elevated for 
RETΔE345 compared to RET (p=0.0439, p=0.0411 respectively), and also for RETΔE345 
co-expressed with GFRα1 compared to full-length RET co-expressed with GFRα1 
(p=0.0106, p=0.0096, respectively).  However, levels of phospho-Tyr905 and phospho-
Tyr1062 were unchanged for RETΔE3 compared to RET, and also for RETΔE3 co-
expressed with GFRα1 compared to full-length RET co-expressed with GFRα1.  Taken 
together, these data suggest that RETΔE3 has a similar activation level to full-length 
RET, whereas RETΔE345 has an elevated activation level compared to RET in a ligand-
independent manner.  Additionally, the lower total phosphotyrosine level for RETΔE345 
compared to phospho-Tyr905 and phospho-Tyr1062 suggests that one or more of the 
other tyrosine residues in RET is not phosphorylated as highly as Tyr905 and Tyr1062 
compared to full-length RET. 
 
Discussion 
Alternative splicing of precursor mRNA is one of many processes that mediates 
gene regulation in metazoans, and the frequency of alternative splicing increases with 
species complexity (Pan et al., 2008, Wang et al., 2008).  For example, of the 
approximately 25,000 genes encoded by the human genome, ~95% produce transcripts 
that are alternatively spliced (Wang et al., 2008, Pan et al., 2008). By expanding the 
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proteome through the synthesis of various protein isoforms, alternative splicing allows 
for increased protein diversity with isoforms performing different biological functions.   
Here we provide evidence for two alternative splicing events in Ret that, in 
combination with Ret9 or Ret51 alternative splicing, give rise to at least five Ret 
transcripts (Fig. 2.2C). The splicing events for RETΔE3 and RETΔE345 have only been 
previously described in human tissues (Lorenzo et al., 1995). Because an additional Ret 
transcript, RET43, is only expressed in humans, we examined the expression of RETΔE3 
and RETΔE345 in additional vertebrate tissues to determine whether these might also be 
human specific transcripts (Myers et al., 1995, Carter et al., 2001). To this end, we 
discovered that RETΔE3 and RETΔE345 are not human-specific RET transcripts, but are 
also expressed in normal developing tissues of zebrafish, mice and rats (Fig. 2.1C). 
Functionally important transcripts are transcriptionally conserved between species, 
arguing that RETΔE3 and RETΔE345 have physiologically important functions.   
 Analysis of an experimentally validated structural model for the RET cadherin-like 
domains 1-4 was made to evaluate the consequence of exon deletions of RET 
alternative splicing on the ligand binding and activation characteristics of RETΔE3 and 
RETΔE345 (Fig. 2.1B). Previous experiments indicate that the GDNF-GFRα1 complex 
binds directly to CLD4 and the CRD (Amoresano et al., 2005).This suggested that both 
RETΔE3 and RETΔE345 should be able to bind to the GDNF-GFRα1 complex, and indeed 
this interaction was observed not only for GFRα1, but also for GFRα2, GFRα3 and 
GFRα4 (Fig. 2.4). While it was originally thought that CLD1-3 was involved in direct 
binding from results obtained through mutagenesis studies, a direct interaction between 
CLD1-3 and the GDNF-GFRα1 complex has not been observed (Amoresano et al., 
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2005, Kjaer and Ibanez, 2003). Instead, it has been proposed that CLD1-3 contributes 
to the stability of the tertiary structure of the GDNF-GFRα1-RET complex by forming a 
secondary dimerization site to trap the GDNF-GFRα1 binary complex (Goodman et al., 
2014). These studies predict that RETΔE3, which forms a fused CLD1-CLD2 region, 
likely gives rise to a less stable tertiary GDNF-GFRα1-RET complex compared to full-
length RET.  This may result in a receptor variant with differential ligand binding 
specificities.  Fibroblast growth factor receptors (FGFRs) are a subfamily of four RTKs 
that are receptors for fibroblast growth factors (FGFs), of which there are 18 ligands 
(Turner and Grose, 2010). Alternative splicing of the FGFRs in the region coding for the 
extracellular ligand-binding domain of the receptors allows for differential ligand binding.  
It is possible that the alternative splicing responsible for RETΔE3 similarly modifies GFL-
GFRa affinity. Alternatively, the truncated extracellular domain of RETΔE3 may cause 
alterations in the conformational changes that occur upon GFL-GFRa binding that 
induces receptor autophosphorylation.  This would cause different autophosphorylation 
kinetics in RETΔE3 compared to full-length RET and, therefore, differential activation of 
downstream second messenger cascades. Biochemical experiments using an in vitro 
system that allows for the direct ligand activation of RETΔE3 or full-length RET in 
isolation will be necessary to distinguish between these possibilities. 
 The large deletion in the extracellular domain of RETΔE345, including the Ca2+ 
binding domain which is important for RET folding and ligand-dependent signaling, is 
predicted to have dramatic effects on RETΔE345 activation. Indeed, it is likely that 
RETΔE345 functions as a constitutively active form of RET, consistent with the 
mechanistic data shown in Figure 2.6. Autophosphorylation of RETΔE345 is increased 
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compared to full-length RET in the presence and absence of GFRα1 in vitro (Fig. 2.6B). 
Constitutively active RTKs have not been found to exist in normal tissues, and usually 
arise from germline and somatic mutations where they are most commonly found to 
cause neoplasias. Activating mutations in RET have been shown to be responsible for 
multiple endocrine neoplasia, type 2, including neoplasias such as medullary thyroid 
carcinoma and pheochromocytomas (Mulligan, 2014). Unlike other constitutively active 
forms of RET, RETΔE345 may be post-transcriptionally or translationally regulated in vivo 
in a manner that is not recapitulated in the in vitro system used here.  In this way, the 
signaling of RETΔE345 may be under tight regulation in order for this isoform to perform 
specific functions in vivo.  Importantly, this is the first constitutively active RTK identified 
in normal tissues (Fig. 2.2). 
To interrogate the functions of RETΔE3 and RETΔE345 in primary neurons and 
tissues, we attempted to generate isoform specific antibodies. Likewise, we also tried to 
create siRNAs to selectively knockdown RetΔE3 and RetΔE345 transcripts. Neither of 
these experimental approaches were successful at targeting RETΔE3 and RETΔE345 
without also affecting full-length RET.  Therefore, in order to determine the physiologic 
functions of RETΔE3 and RETΔE345, a transgenic approach in a vertebrate will be 
required to selectively remove these individual transcripts. This could be accomplished 
by deleting specific introns and fusing the flanking exons in frame to inhibit exon 
skipping (e.g. remove intron 3 and fuse exons 2 and 3 together to inhibit alternative 
splicing for RetΔE3). How this approach would affect RET expression, and other splicing 
events, however, is unknown.  In addition, due to the invariably coincident expression of 
RetΔE3 and RetΔE345 in the same tissues as Ret, it is possible that full-length RET may 
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compensate for the functions of RETΔE3 and RETΔE345.  As an alternative approach, 
production of knock-in animals in which only RetΔE3 or RetΔE345 is expressed would 
determine whether these isoforms are capable of supporting the normal development of 
the nervous system and kidneys.    
 Lastly, to gain a mechanistic understanding of the factors responsible for the 
alternative splicing of Ret, it would be interesting to explore RNA motifs encoding exon 
splicing enhancers within the locus that impact the formation of RetΔE3 and RetΔE345. 
Understanding the spliceosome machinery involved in this process may help us 
understand why the expression of these transcripts are elevated in tumors, such as in 
pheochromocytomas (Lorenzo et al., 1995). Overall, it may be necessary to return to a 
disease model, such as neuroendocrine gland tumors where these RET transcripts 
were originally identified, and use the pathobiology to understand the signaling 
capacities of RETΔE3 and RETΔE345, in order to identify their functions in normal 
development. 
 
EXPERIMENTAL PROCEDURES 
Molecular modeling - This analysis was performed as previously described (Goodman 
et al., 2014).  Models of cadherin-like domains 1 to 4 were taken from PDB code 4UX8 
defined by a combination of EM and SAXS analyses.  The figure was made using 
PyMol software (Schrodinger, USA). 
 
RNA isolation, RT-PCR, qPCR - Total RNA was isolated from zebrafish, mouse or rat 
tissues using TRIzol reagent (Thermo Fisher Scientific) according to manufacturer’s 
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instructions.  cDNA synthesis was performed from 1 µg of total RNA to generate polyA 
first-strand cDNA using the SuperScript III First-Strand Synthesis System for RT-PCR 
kit (Life Technologies).  For RT-PCR reactions with amplicons less than 200 bp, GoTaq 
Green master mix (Promega) and species-specific oligonucleotide primers for Ret, 
RetΔ3, and RetΔ345 were used.  RT-PCR reactions with amplicons greater than 200 bp 
were performed using the Phusion High-Fidelity DNA Polymerase kit (NEB) following 
the manufacturer’s instructions.  qPCR was performed using FastStart Universal SYBR 
Green Master Mix (Roche) and run on a QuantStudio 6 Flex Real-Time PCR System 
(Thermo Fisher Scientific).  Quantitative analyses were performed by calculating the 
ΔCt (Ct of transcript divided by Ct of the housekeeping gene, actin) for each gene 
analyzed and transforming that value to log2.  These values are reported as the relative 
expression. 
 
Primer sequences: The primers used for this study are as follows: ZF.RetFL.F: 5’-TCG 
TAG TTT ACG CAG CGG CTC A-3’; ZF.RetFL.R: 5’-TCG CGA TTT TCA GTG ATG 
TG-3’; ZF.Ret3.F: 5’-CAG TAG TTT ACG ATC TTC TGT ACC G-3’; ZF.Ret3.R: 5’-TTC 
AGT GTC AGT CCC GTT GA-3’; ZF.Ret345.F: 5’-CAG TAG TTT ACA GCT GAA ACT 
CAG TC-3’; ZF.Ret345.R: 5’-TGA CAT TGG AGA AGC GAA TG-3’; Mouse.RetFL.F: 5’-
AGC ATC CGC AAT GGT GGT TT-3’; Mouse.RetFL.R: 5’-TGT TCT CCC TGA CTC 
GGA AG-3’; Mouse.Ret3.F: 5’-AGC ATC CGC AGG GAT AGT CT-3’;  Mouse.Ret3.R: 
5’-ACA CTG TCA CTG GGA AGG AC-3’; Mouse.Ret345.F: 5’-AGC ATC CGC AAG 
CTG ATT CT-3’; Mouse.Ret345.R: 5’-TTC ACT GGG AAG GAG TAG GC-3’; 
Rat.RetFL.F: 5’-AGC ATC CGC AAT GGC GGC TT-3’; Rat.RetFL.R: 5’-TAG CAT GCG 
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GAA CTG GTA GA-3’; Rat.Ret3.F: 5’-AGC ATC CGC AGG GAC GGT CT-3’; 
Rat.Ret3.R: 5’-CCG CTT AAA CTC CAC CAC AG-3’; Rat.Ret345.F: 5’-AGC ATC CGC 
AAG CTG GTT CT-3’; Rat.Ret345.R: 5’-TAG GCC ATG GGT AGG TTC AG-3’; 
Mouse.Ret9.R: 5’-ATT TAC TGT CCA TTG CAA GGC-3’; Mouse.Ret51.R: 5’-CCT ATC 
AGT GCT TTA AGT CTG-3’. 
 
Mice – Wild-type C57BL/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME).   Ret-/- mice have been previously described and were maintained in a 
mixed genetic background (Schuchardt et al., 1994). For timed matings, noon of the day 
on which a vaginal plug was detected was considered as E0.5. All housing and 
procedures performed on mice were approved by the University of Michigan Animal 
Care and Use Committee (UCUCA). 
 
Detergent extraction and preclearing of whole tissues – Tissues were harvested, placed 
in a 2.0 mL tube with 250 µL immunoprecipitation (IP) buffer lacking NP-40 (Tris-
buffered saline [TBS], pH 7.4, 10% glycerol, 500 µM sodium vanadate and protease 
inhibitors) along with a steel grinding ball (5mm, 69989, Qiagen, Valencia, CA) and 
mechanically homogenized using a TissueLyzer II (Qiagen) for 2 minutes at a frequency 
of 20 Hz. Following this, 250 µL of 2% NP-40-containing IP buffer was added to 
homogenates and incubated for one hour at 4°C under gentle agitation. Homogenates 
were then centrifuged for 10 minutes at 16,000 x g and subjected to an initial 
preclearing step with protein A and protein G alone at 4°C for two hours under gentle 
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agitation.  A second preclearing step was performed with protein A, protein G and a 
species-matched nonspecific control IgG for two hours under gentle agitation.  
 
Immunoprecipitations and immunoblotting - Plates were placed on ice, gently washed 
twice with 1X PBS, pH 7.4, and lysed with modified RIPA buffer (TBS, pH 7.4, 10% 
glycerol, 1% Triton X-100, 0.1% SDS, 500 µM sodium vanadate and protease 
inhibitors). Proteins were immunoprecipitated using anti-RET9 (goat, Santa Cruz), anti-
RET51 (goat, Santa Cruz), anti-HA (mouse, Millipore), or anti-FLAG (rabbit, Cell 
Signaling) selective antibodies.  Immunoprecipitates were subjected to SDS-PAGE 
followed by electroblotting onto polyvinylidene difluoride membranes (PVDF, Immobilon 
P; Millipore Corporation).  Immunoblotting was performed on blots using antibodies 
selective for RET (1:500, goat, R&D), HA (1:5000, rabbit, Cell Signaling), Trk (1:1000, 
rabbit, Santa Cruz), phospho-tyrosine (1:1000, mouse, Millipore), phospho-RET (Tyr905) 
(1:500, rabbit), or phospho-RET (Tyr1062) (1:500, rabbit).  Phospho-RET (Tyr905) and 
phospho-RET (Tyr1062) have been previously described (Tsui-Pierchala et al., 2002a). 
Lysates collected prior to immunoprecipitations served as loading controls to assess 
protein expression levels, and were also subjected to immunoblotting for actin (1:1000, 
goat, Santa Cruz). Each biochemical experiment was performed three to four times with 
similar results.  
 
Mammalian cell culture and transfections − NIH/3T3 and HEK293T cells (ATCC) were 
maintained at 37°C with 5% CO2 in DMEM medium supplemented with FBS (10% by 
volume) and a penicillin/streptomycin/glutamine (PSQ) mixture. Cells were plated into 6-
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well tissue culture plates and allowed to proliferate until cells were 70% confluent.  
Transfections of NIH/3T3 and HEK293T cells were performed using Lipofectamine 2000 
according to the manufacturer’s instructions (Invitrogen).  For experiments testing the 
interaction of proteins, a total of 4 µg of plasmid DNA was added per well, using a GFP 
plasmid as a control for transfecting equal amounts of DNA.  For in vitro activation 
experiments, 2 µg of HA::GFRα1 and 1 µg of one of the RET isoforms were transfected 
for a total of 3 µg of DNA per condition, with GFP plasmid used as a control for 
transfecting equal amounts of DNA. RET51ΔE3 and RET51ΔE345 constructs were 
subcloned from RET51 constructs into pcDNA3.1 (Thermo Fisher Scientific).  A Ret51 
construct encoding mouse RET51 fused at the C-terminus with an HA epitope tag 
(RET51::HA) was acquired from Dr. Ben Allen.  This plasmid was subcloned to create 
similarly tagged Ret51ΔE3 and Ret51ΔE345 constructs, which were sub-cloned into 
pLentilox-IRES-GFP (University of Michigan Vector Core). The HA::GFRα1 (mouse) 
plasmid was generously donated by Dr. Ben Allen. HA::GFRα2 (rat), HA::GFRα3 
(mouse), and HA::GFRα4 (chicken) plasmids were generously donated by Dr. Carlos 
Ibáñez.  The TrkA (rat) plasmid was generously donated by Dr. Christin Carter-Su. 
 
Quantification of Immunoblots - Scanned images of X-ray films were imported into 
ImageJ (National Institutes of Health) and processed using the gel analysis tool. 
Integrated density values obtained from immunoblotting were reported as mean values 
± SEM, with arbitrary units on the vertical axis. Values were normalized to the level of 
RET51 phosphorylation in each experiment.  Statistical analyses were performed using 
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a Student’s t-test for each experiment, and all biochemical experiments were performed 
at least three times with similar results. 
 
Immunocytochemistry – Transfected cells that were plated on glass coverslips were 
fixed for 8 minutes in 4% PFA.  Cells were washed twice in 1X PBS, and briefly blocked 
in immunofluorescence blocking solution (3% BSA, 1% normal donkey serum in 1X 
PBS, pH 7.4) with or without 0.1% Triton X-100.  Primary antibodies were diluted in 
blocking buffer [RET (1:50, goat, R&D), HA (1:1000, mouse, Millipore)], and slides were 
incubated at 4°C overnight.  Cells were washed twice with 1X PBS and then were 
incubated at room temperature for one hour with secondary antibodies [donkey anti-
mouse Alexa Fluor 633 (Thermo Fisher Scientific), donkey anti-goat 543 (Biotium)] 
diluted in blocking solution.  Lastly, cells were washed three times in 1X PBS and 
mounted with DAPI Fluoromount-G (Southern Biotech).  Cells were imaged using a 
Zeiss Axiovert 200 M epifluorescence microscope with a 40X objective. 
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Figure 2.1: Removal of exons 3 or 3, 4 and 5 of RET creates proteins with large 
deletions in the extracellular domain, and transcripts encoding these receptors are 
expressed in multiple organisms. 
(A) Comparison of the amino acid sequences of RET between zebrafish, mice, rats, and 
humans was performed, and the conservation within each exon is indicated by color.  
Interestingly, the amino acids encoded in exons 3, 4, and 5 are the least conserved.  
Additionally, the impact of exon skipping on the extracellular domain within the protein is 
shown. (B) RetΔE3 and RetΔE345 transcripts are detectable in zebrafish (Danio rerio), mice (Mus 
musculus), and rats (Rattus norvegicus) by qPCR.  Like human RETΔE3 and RETΔE345, 
alternative splicing of exon 3 or exons 3, 4 and 5 in these vertebrates are predicted to encode 
full-length, transmembrane RET proteins with deletions in the extracellular domain. (C) 
Deleted regions within the crystal structure of the extracellular domain of RET are colored in 
red. 	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Figure 2.2: RetΔE3 and RetΔE345 are dynamically expressed throughout development, and 
RET proteins with similar molecular weights to RETΔE345 are detect in vivo. 
(A) Expression of Ret, RetΔE3 and RetΔE345 in mouse brain (E15.5, E19.5 P3), spinal cord 
(E15.5, E19.5, P3, adult), and kidney (E15.5, E19.5 P3, adult) by qPCR is shown as relative 
expression compared to actin. (B) Expression of Ret, RetΔE3 and RetΔE345 in mouse 
sympathetic (E19.5, P3, adult) and DRG sensory neurons (E15.5, E19.5, P3, adult) by qPCR 
is graphed as in (A). (C) cDNA from E19.5 DRGs was synthesized from polyA RNA, and RT-
PCR was performed to determine the presence of Ret transcripts with both 5’ and 3’ 
alternative splicing.  Ret9, Ret9ΔE3, Ret9ΔE345, Ret51, and Ret51ΔE345 transcripts were 
identified. (D) E18.5 mouse brains were lysed and immunoprecipitations for RET9 or RET51 
were performed.  Immunoblotting for RET detected full-length RET9 and RET51, as expected.  
The presence of RET9 and RET51 proteins at the same molecular weight as RETΔE345 
suggested the existence of RET9ΔE345 and RET51ΔE345 isoforms. 
A
B Ret
RE
T5
1
RE
T5
1∆
E3
RE
T5
1∆
E3
45
Re
t +
/+
Re
t -
/-
Re
t +
/+
Re
t -
/-
IP: Ret9 IP: Ret51
IB: Ret
Super.
IB: Actin
Mr
250
130
100
75
42
> >
> >
+ RT + RT- RT - RT
Re
t9
Re
t9
ΔE
3
Re
t9
ΔE
34
5
Re
t9
Re
t9
ΔE
3
Re
t9
ΔE
34
5
Re
t5
1
Re
t5
1Δ
E3
Re
t5
1Δ
E3
45
Re
t5
1
Re
t5
1Δ
E3
Re
t5
1Δ
E3
45
1 
Kb
 L
ad
de
r
C D
Ret
Brain Spinal Cord Kidney
RetΔE3
Brain Spinal Cord Kidney
RetΔE345
Brain Spinal Cord Kidney
DRG SCG
RetΔE3
DRG SCG
RetΔE345
DRG SCG
E19.5 Mouse DRG
E18.5 Mouse Brain
	   63	   
RE
T5
1Δ
HARETGFP
Tr
ito
n 
X-
10
0
N
o 
Tr
ito
n 
X-
10
0
G
FP
 V
ec
to
r
DAPI
Tr
ito
n 
X-
10
0
N
o 
Tr
ito
n 
X-
10
0
R
E
T5
1:
:H
A-
IR
E
S
-G
FP
Tr
ito
n 
X-
10
0
N
o 
Tr
ito
n 
X-
10
0
R
E
T5
1Δ
E3
::H
A-
IR
E
S
-G
FP
Tr
ito
n 
X-
10
0
N
o 
Tr
ito
n 
X-
10
0
R
E
T5
1Δ
E
34
5 :
:H
A-
IR
E
S
-G
FP
A B C D
E F G H
I J K L
M N O P
Q R S T
U V W X
Y Z A’ B’
C’ D’ E’ F’
	   64	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: RETΔE3 and RETΔE345 are trafficked to the cell surface. 
NIH/3T3 cells were transfected with GFP (A-H), Ret51::HA (I-P), Ret51ΔE3::HA (Q-X) or 
Ret51ΔE345::HA (Y-F’).  Constructs for the RET51 isoforms were bicistronic, allowing for 
expression of GFP as an indicator for positive transfection, which was encoded by an IRES-
GFP following RET cDNA sequences.  Cells were washed in 1X PBS and fixed briefly in 4% 
PFA 24 hours post-transfection.  Cells were then blocked in immunofluorescence blocking 
solution with or without Triton X-100 to allow for cell membrane permeabilization.  In the 
absence of Triton X-100, antibodies specific for the RET extracellular domain were able to 
bind to RET51::HA (K), RET51ΔE3::HA (S), and RET51ΔE345::HA (A’).  However, using an 
antibody against the HA epitope which would detect the C-terminus located intracellularly for 
RET51::HA (L), RET51ΔE3::HA (T), and RET51ΔE345::HA (B’) showed no binding/fluorescence 
in the absence of Triton X-100.  When immunofluorescence blocking solution with Triton X-
100 was used, fluorescence was detected using the anti-HA antibody for RET51::HA (P), 
RET51ΔE3::HA (X), and RET51ΔE345::HA (F’).  These data show that RET51ΔE3 and RET51ΔE345 
are trafficked to the cell surface similarly to full-length RET51. 	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Figure 2.4: RETΔE3 and RETΔE345 bind to GFRα1, GFRα2, GFRα3 and GFRα4. 
RET51, RET51ΔE3 and RET51ΔE345 were co-transfected with HA epitope tagged GFRα1 (A), 
GFRα2 (B), GFRα3 (C), or GFRα4 (D).  Immunoprecipitations were performed using an HA 
antibody to select for the GFRαs.  Immunoblotting for RET showed the interaction of 
RET51ΔE3 and RET51ΔE345 with all four GFRα proteins.  Co-transfection of HA::GFRα1, 
HA::GFRα2, HA::GFRα3 or HA::GFRα4 with TrkA was performed as a negative control, and 
as expected, TrkA did not associate with any of the GFRαs. 	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Figure 2.5: RETΔE3 and RETΔE345 can heterodimerize with full-length RET. 
(A) HA epitope tagged RET51 (RET51::HA) was co-transfected with untagged RET51ΔE3 or 
RET51ΔE345 in HEK293T cells.  Immunoprecipitations were performed with an HA antibody to 
select for RET51::HA.  Immunoblotting for RET51 showed co-immunoprecipitation of 
RET51ΔE3 and RET51ΔE345 with full-length RET51.  (B) A similar experiment was performed 
using FLAG epitope tagged RET51ΔE345 (FLAG:: RET51ΔE345).  Immunoprecipitations with an 
anti-FLAG antibody selected for FLAG:: RET51ΔE345.  Immunoblotting for RET51 demonstrated 
the association of RET51 and RET51ΔE3 with FLAG:: RET51ΔE345. Co-transfections with TrkA 
were performed for both experiments as a negative control, and immunoblotting for TrkA 
showed no binding with either RET51::HA or FLAG::RET51ΔE345, as expected.   	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Figure 2.6: RETΔE345 displays increased ligand-independent activation compared to full-
length RET. 
(A) RET51 was co-transfected with HA epitope tagged GFRα1 in NIH/3T3 cells.  
Immunoprecipitations were performed with a RET51 antibody to select for the RET isoforms.  
Immunoblotting for phospho-tyrosine and RET was performed, and integrated density values 
were calculated for each. (B) Pre-IP lysates from the previous experiment were subjected to 
SDS-PAGE, and Western blotting was performed to determine the levels of residue-specific 
tyrosine phosphorylation of RET.  Immunoblotting was performed for phospho-RET (Tyr905), 
phospho-RET (Tyr1062), and RET, and integrated density values were calculated for each.  (C) 
Ratios of phospho-RET/RET, (D) phospho-RET (Tyr905)/RET, and (E) phospho-RET 
(Tyr1062)/RET are reported, with values normalized to RET51.  A single asterisk (*) denotes a 
p-value < 0.05 and a double asterisk (**) denotes a p-value < 0.01. 	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CHAPTER 3 
LOSS OF RET RESULTS IN A DECREASE IN APOPTOSIS DURING 
PROGRAMMED CELL DEATH 
Summary 
Target-derived neurotrophic factors, such as the neurotrophins and the glial cell-
line derived neurotrophic factor (GDNF) family of ligands (GFLs) are crucial components 
aiding in the establishment of proper connections between neurons and their targets. In 
the peripheral nervous system (PNS), GFLs signal through their common receptor 
tyrosine kinase, RET, to produce signals critical for neuronal survival, migration, and 
axonal growth. Recently, we discovered that RET associates with p75, a member of the 
tumor necrosis factor family of death receptors, in vitro and in vivo. This interaction is 
surprising because p75 is a critical mediator of apoptosis upon activation by 
proneurotrophins, while RET is canonically involved in pro-survival signaling as a 
receptor for the GFLs. Interestingly, the interaction between p75 and RET is increased 
upon stimulation with apoptotic signals that induce p75-dependent apoptosis in 
sympathetic neurons. These findings suggest a functional role of RET in p75-mediated 
pro-apoptotic signaling.  Furthermore, we find that genetic deletion of Ret results in a 
decrease in programmed cell death (PCD) in vivo.  Unexpectedly, genetic deletion of 
p75 resulted in no difference in programmed cell death in vivo.  Collectively, these data 
implicate RET as a novel co-receptor for p75-mediated apoptosis in vitro, but the in vivo 
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mechanisms behind p75-mediated cell death during PCD may need further 
evaluation. 
Introduction 
During the development of the peripheral nervous system there is a widespread 
overproduction of neurons, with most populations producing twice the number of 
neurons that are present in adulthood (Oppenheim, 1991).  Neurons that do not make 
appropriate or sufficiently extensive connections and, therefore, do not receive a 
sufficient amount of target-derived survival factors are eliminated through a process 
known as programmed cell death (PCD) (Oppenheim, 1991). One population of 
neurons that has been used extensively as a model to study this process is post-
ganglionic sympathetic neurons of the superior cervical ganglia (SCG) (Glebova and 
Ginty, 2005). In the mouse SCG, PCD occurs late perinatally through early postnatal 
stages (~E17-P20) (Bamji et al., 1998), and during this time, sympathetic neurons 
require nerve growth factor (NGF) for their survival (Levi-Montalcini, 1987). NGF is 
secreted in a limited amount from target tissues, and binds to the receptor tyrosine 
kinase, TrkA, located on sympathetic axons (Glebova and Ginty, 2005).  Upon binding, 
this NGF-TrkA complex is retrogradely trafficked to the cell body and promotes neuronal 
survival by inhibiting apoptosis in these “winning” cells (Ehlers et al., 1995, Riccio et al., 
1997). 
In addition to the competition for survival factors, evidence also points to the 
involvement of pro-apoptotic factors in developmental cell death via TNF family 
receptors such as the p75 neurotrophin receptor (p75NTR, NGFR, TNFRSF16) (Bamji 
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et al., 1998, Deppmann et al., 2008). p75 is a promiscuous receptor that interacts with 
TrkA, thereby increasing its affinity for NGF, as well as enhancing TrkA-mediated 
survival signaling (Verdi et al., 1994, Barker and Shooter, 1994).  In the absence of Trk 
receptors, however, p75 can function as a receptor for members of the neurotrophin 
family, as well as proneurotrophins, and signaling in this context can trigger cell death 
pathways (Teng et al., 2010). It has been proposed that “winning” neurons release pro-
apoptotic p75 ligands, such as brain-derived neurotrophic factor (BDNF), that enhance 
apoptosis in the vulnerable “losing” neurons that are not protected by the survival 
pathways activated by NGF-TrkA/p75 signaling (Teng et al., 2010). Genetic evidence in 
support of this competition model includes the significant lengthening of the period of 
PCD in the SCG of p75 null mice (Bamji et al., 1998, Deppmann et al., 2008).  
An additional neurotrophic factor receptor, RET, is also expressed in the SCG 
during the period of PCD (Enomoto et al., 2001), but its function during this time has not 
been elucidated.  Like TrkA, RET is a receptor tyrosine kinase, but it is activated by a 
family of four growth factors known as the glial cell line-derived neurotrophic factor 
(GDNF) family ligands (GFLs), which includes GDNF, neurturin, artemin and persephin 
(Airaksinen and Saarma, 2002).  These ligands do not bind directly to RET, but bind to 
one of four cognate glycosylphosphatidylinositol (GPI) anchored co-receptors known as 
the GDNF Family Receptor-αs (GFRαs) (Airaksinen and Saarma, 2002). Once this 
GFL-GFRα complex forms, it can then bind to RET, allowing for activation of the 
receptor. RET signaling has been shown to be critical for survival in a number of 
neuronal populations including subpopulations of sensory neurons of the dorsal root 
ganglia (DRG) (Luo et al., 2009, Golden et al., 2010), enteric neurons (Schuchardt et 
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al., 1994, Schuchardt et al., 1996) and γ-motor neurons of the motor nervous system 
(Gould et al., 2008).  Moreover, specifically in the SCG, RET signaling has been shown 
to be important for sympathetic chain ganglia migration, coalescence of the ganglia and 
early axon pathfinding (Enomoto et al., 2001).  These deficits lead to the early apoptotic 
death of SCG neurons prior to the period of PCD, thereby limiting investigation of the 
role of RET signaling in PCD of the SCG.   
We report here that Ret is expressed in a subset of sympathetic neurons of the 
SCG during PCD that express both p75 and tyrosine hydroxylase.  We also observe 
that these Ret positive neurons are lost during this developmental time window.  
Furthermore, we find that RET can interact with p75 both in vitro and in vivo, and that 
this interaction is enhanced in the presence of apoptotic stimuli, suggesting that RET 
may be able to enhance p75-mediated cell death.  Genetic deletion of Ret in the 
developing embryo using a tamoxifen inducible Cre recombinase at a late perinatal time 
showed that loss of RET leads to a reduction in cell death during PCD.  Surprisingly, 
genetic deletion of p75 utilizing both a tamoxifen inducible Cre recombinase approach 
as well as a germline deletion approach showed no difference in the amount of cell 
death occurring between mutant or control animals.  This potential dichotomy will be 
considered in detail in the discussion of this chapter as well as in Chapter 4. 
RESULTS 
Ret is expressed in a subset of p75-positive noradrenergic neurons during 
programmed cell death 
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RET is required for the proper differentiation of sympathetic precursors, for 
migration of the sympathetic chain ganglia, and also for sympathetic axon guidance 
during development (Enomoto et al., 2001).  Within the superior cervical ganglia (SCG), 
Ret expression is high until E15.5 (Enomoto et al., 2001).  After this time, Ret 
expression becomes restricted to a subset of neurons within the SCG, but its role during 
this developmental period has not been elucidated (Enomoto et al., 2001). Interestingly, 
late prenatal expression of Ret overlaps with the period of PCD, and we postulated that 
RET may be involved in this process. Using a reporter line in which GFP was knocked 
into the Ret locus, Enomoto et al. showed that at any time throughout PCD, 
approximately 5-6% of neurons in the SCG are Ret positive (Enomoto et al., 2001).  
However, this approach did not allow for the authors to distinguish if a subset of 
neurons were Ret positive and remained Ret positive during this time, or if cells that 
upregulated Ret were then actively being turned over.  To examine this possibility, we 
performed a tamoxifen pulse experiment using Rosa26LSL-tdTomato mice crossed to Ret-
Cre/ERT2, in which a tamoxifen inducible Cre recombinase is knocked into the 
endogenous Ret locus (Luo et al., 2009).  By administering tamoxifen to these animals, 
cells that are endogenously expressing Ret at that time are labeled with fluorescent 
tdTomato protein.  We administered tamoxifen (100 μg) to pregnant dams at embryonic 
day 16.5 (E16.5) or 18.5 (E18.5), and then isolated SCGs from embryos at E19.5 (Fig. 
3.1A).  Because a consistent percentage of cells are Ret positive during this time period 
(Enomoto et al., 2001), we hypothesized that if Ret positive cells were turning over, the 
mice receiving tamoxifen at E16.5 would have fewer Ret positive cells than the animals 
receiving tamoxifen at E18.5.  However, if a stable population of cells were expressing 
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Ret, then we would expect to observe a similar number of Ret positive cells at E19.5 
from animals injected at either timepoint.  Interestingly, we observed a decrease in the 
number of Ret positive cells from pups receiving tamoxifen at E16.5 compared to those 
receiving tamoxifen at E18.5, suggesting that these Ret-expressing cells are lost 
throughout this period of developmental cell death (Fig. 3.1B).  Consistent with this 
hypothesis, many of the Ret-expressing neurons labeled at E16.5 appeared atrophic at 
E19.5 with the presence of early pyknotic nuclei forming, indicating these neurons were 
starting to undergo apoptosis (Fig. 3.1C). However, when staining for the late apoptotic 
marker, cleaved caspase-3, we did not observe co-localization of cleaved caspase-3 in 
Ret-expressing cells (data not shown). This lack of co-localization is likely due to 
degradation of tdTomato protein in the Ret-expressing cells at this late apoptotic time 
point. 
p75 is critically involved in programmed cell death in the SCG (Bamji et al., 1998, 
Deppmann et al., 2008); to determine whether Ret was co-expressed with p75 in the 
same cells within the SCG, Rosa26LSL-tdTomato; Ret-Cre/ERT2 mice were again used and 
pregnant dams were given tamoxifen at E18.5.  The embryos were collected one day 
later and SCGs were isolated and then processed for cryosectioning.  
Immunofluorescence staining for p75 was performed, and the co-expression of Ret 
labeled by tdTomato and p75 was assessed.  As a control, the p75 antibody was 
validated by immunostaining p75 null SCGs (Fig. 3.2C).  Of the small subset of neurons 
that were Ret-positive, 100% of these Ret-positive cells were also p75-positive (Fig. 
3.2A), indicating that p75 is co-expressed in Ret-positive SCG neurons.   
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In the stellate ganglia (STG), the majority of cells are noradrenergic, but a 
subpopulation of Ret-positive cholinergic neurons has been described that emerge 
during late prenatal development (Huang et al., 2013). To determine if this subset of 
Ret-positive neurons in the SCG was not noradrenergic, and therefore most likely 
cholinergic, immunofluorescence staining for tyrosine hydroxylase (TH), a marker for 
noradrenergic neurons, was performed. We observed that Ret-positive neurons were 
also co-expressing TH, indicating that, unlike in the STG, Ret-positive neurons in the 
SCG are not a subpopulation of cholinergic neurons (Fig. 3.2B).  Taken together, these 
data indicate that Ret-expressing cells in the SCG are noradrenergic, co-express with 
p75, and actively turn over during PCD. 
p75 and RET interact in vitro and in vivo 
p75 is a promiscuous receptor that directly interacts with other cell surface 
proteins including TrkA, Ephrins, and Nogo receptor (Meeker and Williams, 2014). To 
determine if p75 interacts with RET, we used an in vitro transfection system to co-
express p75 with either the RET9 or RET51 isoforms.  Cells were transfected with 
RET9, RET51 or p75 alone, or were co-transfected with one of the RET isoforms along 
with p75.  Immunoprecipitations were performed using a RET antibody specific for the 
extracellular domain of both RET isoforms. Via immunoblotting, we observe co-
immunoprecipitation of p75 with both RET9 and RET51 (Fig. 3.3A)  Thus, using this in 
vitro system, p75 interacts with RET. 
To determine if p75 and RET interact under basal conditions in vivo, spinal cords 
were isolated from Retfl/fl mice that were crossed to UBC-Cre/ERT2 mice in which the 
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expression of Cre recombinase fused to an estrogen receptor is driven off of the 
ubiquitin C promoter, allowing for the chimeric protein to be ubiquitiously expressed.  
Tamoxifen was administered to females that had recently given birth (P0) to allow the 
transfer of tamoxifen via lactation to the pups.  The pups were sacrificed at P5, and 
spinal cords were isolated.  The tissues were detergent-extracted and 
immunoprecipitations for both RET9 and RET51 were performed to isolate both RET 
isoforms.  To determine whether RET and p75 interact in vivo, immunoblotting of these 
immunoprecipitates was performed for p75; we did observe a robust interaction (Fig. 
3.3B).  As a control to confirm the specificity of our antibodies, immunoprecipitations 
were performed for RET9 and RET51 from spinal cord in which RET had been 
conditionally deleted.  Immunoblotting for p75 from these spinal cords showed no co-
immunoprecipitation (Fig. 3.3B), indicating that our antibodies are specific.  Taken 
together, RET interacts with p75 both in vivo and in vitro. 
Apoptotic stimuli induce the interaction of RET and p75. 
During the process of PCD, apoptosis can occur through several mechanisms 
including lack of NGF trophic support as well as binding of competition factors, either 
BDNF or Pro-BDNF, to p75 (Glebova and Ginty, 2005, Conradt, 2009).  We postulated 
that the interaction of RET and p75 may be induced by the presence of these apoptotic 
signals.  To test this hypothesis, primary sympathetic cultures were treated with one of 
three conditions: (1) α-NGF to create a lack of trophic support (Fig. 3.4A), (2) BDNF 
(Fig. 3.4B) or (3) Pro-BDNF (Fig. 3.4C); the latter two create a pro-apoptotic, 
competition ligand system.  Upon treatment with α-NGF, BDNF and Pro-BDNF, we 
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observed an increase in association over time between RET and p75. These data 
suggest that RET may be involved in p75-mediated apoptotic signaling. 
Apoptosis is reduced during PCD upon deletion of RET 
To determine if Ret is important for enhancing cell death in the SCG during the 
period of programmed cell death, Ret was conditionally deleted from mice at a later 
postnatal stage.  Ret null mice were not used as it has been shown that neuronal 
precursors of the sympathetic nervous system fail to migrate and project axons properly 
(Enomoto et al., 2001). As a consequence, sympathetic nerve trunks are misrouted and 
there is increased cell death of sympathetic neurons due to neuronal precursors failing 
to properly develop (Enomoto et al. 2001).  Instead, Retfl/fl females were mated to 
Retfl/fl;UBC-Cre/ERT2 males.  Pregnant females were given tamoxifen (100 µg) and 
progesterone (50 µg) once a day for four consecutive days beginning at E14.5 (E14.5-
E17.5). Pregnant females were euthanized at E19.5, the embryos were isolated, and 
SCGs were dissected and processed for cryosectioning.  Additionally, spinal cords were 
isolated and detergent extracted, and these extract were subjected to Western blotting 
to determine the level of knockdown of RET protein. We found that greater than 95% of 
RET was eliminated in Retfl/fl;UBC-Cre/ERT2 as compared to control Retfl/fl littermates 
(Fig. 3.5C).  
To assess the amount of cell death occurring in the SCG, immunofluorescence 
staining for cleaved caspase-3 was performed on serially sectioned SCGs. 
Quantification of the number of cleaved caspase-3 positive cells showed a significant 
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decrease in the number of apoptotic cells in Retfl/fl;UBC-Cre/ERT2 mice as compared to 
Retfl/fl littermates (Figure 3.5B). 
Deletion of p75 is reported to result in a reduction of cell death as measured by 
total neuronal cell counts. We employed cleaved caspase-3 staining so that we could 
examine levels of apoptosis as it was actively occurring. To determine how p75 deletion 
affected actively progressing apoptosis, we used the same genetic deletion strategy as 
was used to delete Ret. Germline heterozygous p75 (p75+/-) females were mated to 
p75fl/fl;UBC-Cre/ERT2 males, and as previously performed, pregnant females were 
administered tamoxifen from E14.5-E17.5 to delete p75 in the SCG during PCD.  p75fl/+
pups were used as positive controls while p75fl/-;UBC-Cre/ERT2 pups were analyzed as 
the experimental group.  p75fl/fl;UBC-Cre/ERT2 animals were not used as we were 
unable to achieve consistent knockdown of p75 in these animals (data not shown).  
Surprisingly, there was no significant difference in the number of cleaved caspase-3 
positive cells in the SCG between p75fl/+ and p75fl/-;UBC-Cre/ERT2 mice (Figure 3.6A,B). 
We confirmed, however, that our deletions were effective by immunoblotting for p75 
from spinal cord extracts (Fig. 3.6C). 
Because these results seemed at odds with the previous germline knockout data 
(Bamji et al., 1998), we performed a similar experiment utilizing p75 germline knockout 
mice (p75-/-) to see if we observed a difference in cell death during PCD in the SCG of 
these animals (Bogenmann et al., 2011). Pregnant females were euthanized at the 
same age as the others, E19.5, embryos were isolated, and SCGs were dissected and 
processed for cryosectioning.  Surprisingly, we again observed no significant difference 
in the number of cleaved caspase-3 positive cells in the SCG between p75 null and p75 
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wild-type mice (Figure 3.7A,B), and we confirmed that p75 protein was absent in p75 
null mice (Fig. 3.7C). These data suggest that RET plays a role in programmed cell 
death at E19.5, but that p75 may not. 
Discussion 
During late embryonic development, the function of RET in the developing SCG 
has remained elusive. Experiments in primary neuron cultures suggested that RET 
could interact with p75 (Chris Donnelly, unpublished data), a known pro-apoptotic 
protein that plays a role in programmed cell death during late embryonic and early 
postnatal development. Because RET does not support the survival of neurons in the 
SCG after E15.5 (Enomoto et al., 2001), we hypothesized that, instead, RET may play a 
role in programmed cell death.  
Through a tamoxifen pulse experiment utilizing Rosa26LSL-tdTomato; Ret-Cre/ERT2 
mice, we were able to specifically label cells expressing Ret at late embryonic time 
points.  The SCGs from these embryos were isolated at E19.5, and the number of cells 
expressing tdTomato was quantified.  This experimental design allowed us to determine 
if Ret positive cells were turning over during this time. Although we need to increase our 
sample size, we did observe a reduction in the number of Ret-positive cells at E19.5 
from an earlier tamoxifen pulse at E16.5 versus a tamoxifen pulse at E18.5, suggesting 
that early Ret positive cells are turning over, unlike what had previously been reported 
(Enomoto et al., 2001).  
Additionally, these Ret positive cells were co-expressed with p75 and tyrosine 
hydroxylase, demonstrating that these cells are noradrenergic. It was previously 
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hypothesized that this subset of Ret positive cells was a cholinergic subpopulation, 
similar to the RET and vesicular acetylcholine transporter (VAChT) positive 
subpopulation that arises in the stellate ganglia during late postnatal development 
(Huang et al., 2013). However, it appears that this is not the case. More interestingly, 
we see ubiquitous expression of p75 throughout the SCG at E19.5, potentially due to its 
role in enhancing the survival signaling of TrkA during PCD (Barker and Shooter, 1994, 
Verdi et al., 1994), although this has not been definitively shown to occur. 
Furthermore, we found that RET can interact with p75 both in vitro and in vivo, 
and that this interaction is enhanced in the presence of apoptotic stimuli, suggesting 
that RET may be able to enhance p75-mediated cell death. To assess our hypothesis in 
vivo, Ret was conditionally deleted using a ubiquitously expressed, tamoxifen inducible 
Cre recombinase during late prenatal development.  We observed that a loss of RET 
results in a reduction in the number of cells actively undergoing apoptosis during PCD. 
As a control experiment, we deleted p75 utilizing both a tamoxifen inducible Cre 
recombinase approach as well as a germline deletion approach, and surprisingly, 
observed no difference in either genetic model in the number of cells actively 
undergoing apoptosis in p75-deficient SCGs versus wild-type littermate controls at 
E19.5.  
There are a few potential reasons for the dichotomy between our results and 
previously reported findings that p75 functions in PCD in the SCG. The first difference is 
that we normalized our data to quantify the number of cleaved caspase-3 positive cells 
per area (mm2) to correct for any loss of sections during cryosectioning and/or 
immunostaining, whereas previous studies did not. The second difference is in the 
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assessment of cell death.  In our experiment, we chose to analyze cells actively 
undergoing apoptosis by evaluating the number of cleaved caspase-3 positive cells. 
Previous studies quantified cell death by performing total cell counts, and established 
that PCD occurs between P0 and P20 (Bamji et al., 1998, Deppmann et al., 2008). The 
most appropriate readout for cell death during PCD has yet to be determined. 
Additionally, the previous studies have used a different p75 null mouse model to 
understand the role of p75 in cell death in the SCG. In this mouse, exon 3 of p75 is 
removed (p75Δexon3/Δexon3), and no p75 protein product was detect from this targeted 
deletion, which created a p75 null mouse (Lee et al., 1992). Interestingly, an 
alternatively spliced transcript of p75 was identified in p75Δexon3/Δexon3 mice in which exon 
3 was skipped, and a p75 protein product, s-p75, was identified in primary Schwann 
cells at the appropriate 62 kDa molecular weight (von Schack et al., 2001). While the 
presence of s-p75 is still debated, it is interesting to consider how the protein may 
function; s-p75 is able to bind to Trk receptors, but the protein cannot bind 
neurotrophins (von Schack et al., 2001), thus it would eliminate the “competition factor” 
model that is widely accepted to occur during PCD (Deppmann et al., 2008).   
Due to the controversy surrounding the true deletion of p75 in the p75Δexon3/Δexon3 
mouse, we used the p75 null mouse generated by Bogenmann et al. (Bogenmann et al., 
2011), which is described in greater detail in Chapter 4. Bogenmann et al. showed that 
this was a true p75 knockout, however our analysis in the SCGs of these mice is the first 
evaluation of PCD in this model. Additional experiments are needed to ascertain the 
period of PCD in this line for p75+/+ and p75-/- mice, analyzing both total cell counts and 
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cleaved caspase-3 immunofluorescence staining to determine the most appropriate 
readout for cell death during this time. 
Lastly, it would be interesting to determine if deletion of p75 specifically in Ret 
positive cells results in a loss of cell death. In our genetic approach, other members of 
the TNFR superfamily, such as TNFR1 and DR6, may somehow compensate for the 
ubiquitous deletion of p75. Specifically deleting p75 in this small subset of Ret positive 
cells may avoid this potential compensation. However, the bigger question still remains: 
What is the function of RET in the SCG during late embryonic development? This topic 
is explored further in Chapter 4.  
Experimental Procedures 
Culture and Transfection of Immortalized Cell Lines - NIH/3T3 cells were maintained in 
DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and 1% 
penicillin-streptomycin (Invitrogen, Carlsbad, CA). Cells were plated on 6-well tissue 
culture plates (Falcon) and allowed to proliferate until an approximate density of 50% 
confluence was obtained prior to transfection. Transfections were performed using 
Lipofectamine 2000 according to the manufacturer’s instructions 
(Invitrogen). A total of 5 µg plasmid DNA was added per well, using a plasmid encoding 
GFP to keep the total amount of DNA constant between treatments. The plasmid 
encoding p75 was generously provided by Phil Barker. 
Production of Primary Superior Cervical Ganglion Neurons - Superior cervical ganglia 
(SCGs) were surgically dissected from E19-P1 Sprague-Dawley rats (Charles 
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River, Portage, MI), and enzymatically dissociated via incubation in type I collagenase 
(Worthington) and a 1:1 ratio of HBSS: TrypLE (Invitrogen). Neurons were plated on 
gas-plasma treated 35 mm2 dishes (Harrick Plasma; Ithaca, NY) coated with type I 
collagen (BD Biosciences, San Jose, CA). For all biochemical experiments using rat 
neurons, cells were plated as mass cultures at a density of 3 ganglia per plate. Neurons 
were maintained in minimum essential medium (MEM) containing 50 ng/ml NGF 
(Harlan), 10% (FBS), anti-mitotic agents aphidicolin (3.3 ug/ml) and 5-fluoro-2-
deoxyuridine (20 uM; Sigma, St. Louis, MO), 2 mM glutamine, and 1% penicillin-
streptomycin (Invitrogen, Carlsbad, CA). Neurons were maintained at 37°C with 8% 
CO2 with medium changes every 3-4 days until treatment. Growth factor treatments 
were performed as described in the figure legends. 
Immunoprecipitations and Quantitative Immunoblotting - Cells were stimulated as 
indicated in the figure legends. Following treatment, dishes were placed on ice, gently 
washed with PBS and lysed with immunoprecipitation (IP) buffer (Tris-buffered saline, 
pH 7.4, 1% Nonidet P-40, 10% glycerol, 500 µM sodium vanadate, and protease 
inhibitors) as described previously (Tsui and Pierchala, 2008). Antibodies for α-p75 (5 
ul; 07-476, Millipore, Billerica, MA), α-RET51 and/or α-RET9 (8 µL; C-20 and C-19-G, 
respectively; Santa Cruz Biotechnology) were added along with protein A and protein G 
(Invitrogen, Carlsbad, CA) and incubated overnight at 4°C under gentle agitation. 
Immunoprecipitates were then washed three times with IP buffer and prepared for 
sodium dodecyl sulfate-polyacrylate gel electrophoresis (SDS-PAGE) by adding 2X 
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sample buffer (tris-buffered saline, pH 6.8, 20% glycerol, 10% β-mercaptoethanol, 0.1% 
bromophenol blue and 4% SDS) and boiling the samples for 10 minutes.  
Samples for western blotting were subjected to SDS-PAGE followed by 
electroblotting onto polyvinylidene difluoride membranes (Immobilin P; Millipore). 
Western blot analysis was performed using the following antibodies at the indicated 
concentrations: α-Ret51 (C-20, Santa Cruz, 1:500-1:1000), α-Ret9 (C19R, Santa Cruz, 
1:1000), α-Ret (AF482, R&D, 1:1000), α-p75 (Advanced Targeting Systems, 1:1000), α-
actin (JLA-20, Iowa Hybridoma, 1:2000), α-Sortilin (ab16640, Abcam, 1:1000). Blots 
were developed using a chemiluminescent substrate (Supersignal, ThermoFisher). For 
quantifications, scanned images of X-ray films were imported into ImageJ (National 
Institutes of Health) and processed using the gel analysis tool. Integrated density values 
obtained from immunoblotting were reported as mean values ± SEM, with arbitrary units 
on the vertical axis. Values were normalized to the appropriate control: for co-
immunoprecipitation studies, values were normalized to the precipitated protein, and 
values were normalized to actin (used as a loading control) for all other samples. All 
biochemical experiments were performed at least three times with similar results. 
Detergent Extraction and Immunoprecipitation from Whole Tissues - Spinal cords were 
harvested separately from E19.5/P0 Retfl/fl; UBC-Cre/ERT2 mice, p75fl/-; UBC-Cre/ERT2 
mice or p75-/- mice, placed in a 2.0 mL tube with 250 µL IP Buffer lacking NP-40 along 
with a steel grinding ball (5mm, 69989, Qiagen, Valencia, CA) and mechanically 
homogenized using the TissueLyzer II (Qiagen). The homogenates were then mixed 
with 250 µL of 2% NP-40-containing IP buffer and incubated for 1 hour at 4°C under
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gentle agitation. Homogenates were centrifuged for 10 minutes at 16,100xg and 
subjected to an initial pre-clearing step with protein A and protein G alone at 4°C for 2 
hours under gentle agitation, followed by pre-clearing with protein A, protein G, and a 
species-matched nonspecific control IgG for 2 hours under gentle agitation. Following 
pre-clearing, immunoprecipitations were performed as described above.  
Mouse Lines and Production of Embryos - UBC-Cre/ERT2 (Ruzankina et al., 2007), 
Retfl/fl (Luo et al., 2007), p75fl/fl (Bogenmann et al., 2011), p75-/- (Bogenmann et al., 
2011), Ret-Cre/ERT2 (Luo et al., 2009), and Rosa26LSL-tdTomato mice (Madisen et al., 
2010) have all been previously described, and all mice were maintained in mixed 
genetic backgrounds except for Rosa26LSL-tdTomato which was maintained in a C57BL/6J 
background.  For timed matings, noon of the day on which a vaginal plug was detected 
was considered as E0.5.  Rosa26LSL-tdTomato mice were crossed to Ret-Cre/ERT2 mice 
and given one intraperitoneal injection of tamoxifen (100 µL, 10 mg/mL) at E18.5.  
Additionally, Retfl/fl and p75+/- female mice crossed to either Retfl/fl; UBC-Cre/ERT2 or 
p75fx/fx; UBC-Cre/ERT2 males, respectively, and were given intraperitoneal injections of 
tamoxifen (100 µL, 10 mg/mL) and progesterone (100 µL, 5 mg/mL) consecutively for 
four days beginning at E14.5.  All pregnant females were euthanized at E19.5 and 
embryos were recovered for analysis.  The housing and all procedures performed on 
these mice were approved by the University of Michigan Institutional Animal Care and 
Use Committee (IACUC).  
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Fixation, Sectioning and Immunostaining of Superior Cervical Ganglia - Superior 
cervical ganglia (SCG) were fixed with 4% paraformaldehyde at 4ºC for 2-3 hours, 
washed in PBS three times for 10 minutes, and cryoprotected at 4ºC in 1X PBS 
containing 30% sucrose overnight.  Tissues were embedded in OCT (Tissue Tek), 
frozen and stored at -80ºC until use.  SCGs were serially sectioned at 7 µM on a 
cryostat (CM1950, Leica Biosystems, Germany), with every third section being mounted 
onto the same slide for collective analysis. Tissue sections were washed with PBS and 
blocked with 5% normal goat serum in PBS-T (0.1% Triton X-100 in 1X PBS) for 1 hour, 
followed by incubation with primary antibody (diluted in blocking solution) in a humidified 
chamber overnight at 4ºC. Sections were washed with PBS-T, and incubated with 
secondary antibody (1:500) diluted in blocking solution for 2 hours.  Sections were 
washed again with PBS-T and mounted in fluoromount-G with DAPI (Southern Biotech). 
Images were taken using an inverted fluorescence microscope (Axiovert 200M, Zeiss 
Microsystems, Germany). Antibodies used include α-cleaved caspase-3 (1:300, Cell 
Signaling), α-tyrosine hydroxylase (1:1000, Millipore), and α-p75 [NGFr] (1:200, 
Advanced Targeting Systems).  The number of cleaved caspase-3 positive neurons 
were counted on every third section by an observer naïve to the genotypes of the mice. 
Area measurements of SCGs were performed in the AxioVision software (Zeiss) using 
the “Outline” function.    
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Figure 3.1: Ret is expressed in a subset of neurons during late prenatal 
development. (A) Rosa26LSL-tdTomato females were crossed to Ret-Cre/ERT2 males, and a 
pulse experiment was performed in which pregnant dams were injected with tamoxifen at 
E16.5 or E18.5. SCGs were then isolated from embryos at E19.5. Representative images 
from each set of SCGs are shown. The scale bars denote 50 µm. (B) The number of Ret 
positive cells are quantified from mice injected with tamoxifen at E16.5 (n=3) or E18.5 
(n=2). (C) Ret positive cells from embryos receiving tamoxifen at E16.5 appear apoptotic. 
Arrows designate Ret positive cells that also have karyolytic or pyknotic nuclei.  
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Figure 3.2: Ret is expressed in a subset of p75-positive noradrenergic neurons 
during late embryonic development. (A) Ret is expressed in p75 positive cells of the 
SCG at E19.5. Scale bars denote 200 µm. (B) Ret is expressed in cells also expressing 
tyrosine hydroxylase, a marker of noradrenergic neurons. Scale bars denote 200 µm. 
(C) The specificity of the p75 antibody was determined by performing 
immunofluorescence staining on SCGs from E18.5 wild-type or germline p75 null 
littermates. We observed a loss of all p75 staining in SCGs of p75-/- mice. Scale bars 
denote 200 µm. 
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Figure 3.3: RET and p75 interact in vitro and in vivo. (A) Cells were transfected with 
RET9, RET51 or p75 alone, or were co-transfected with one of the RET isoforms along 
with p75.  Immunoprecipitations for RET were performed, and immunoblotting for p75 
revealed co-immunoprecipitation of p75 with both RET9 and RET51. (B) Spinal cords were 
isolated from P5 Retfl/fl or Retfl/fl;UBC-Cre/ERT2 that had been treated with tamoxifen since 
birth.  Immunoprecipitations for RET9 and RET51 were performed to isolate both RET 
isoforms. Immunoblotting for p75 showed co-immunoprecipitation of p75 with RET under 
basal conditions. In spinal cords where Ret was conditionally deleted, immunoblotting for 
p75 showed no co-immunoprecipitation, indicating that our antibodies are specific. 
Experiments performed and data provided by Olivia Stephens and Chris Donnelly. 
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Figure 3.4: Apoptotic stimuli induce the association of RET and p75 in vitro. 
Primary sympathetic neurons were treated with (A) α-NGF, (B) BDNF or (C) proBDNF 
for 3, 6, 12 or 24 hours. At each time point, immunoprecipitations for RET were 
performed and immunoblotting for p75 was done to assess stimuli dependent 
interactions between RET and p75. Neurons treated with α-NGF (A) had a faster 
association that dissipated over time, whereas neurons treated with BDNF (B) or 
proBDNF (C) showed an increase in association of the two proteins over time. 
Immunoblotting for sortilin (C) a protein that has been shown to associate with p75 for 
proBDNF pro-apoptotic signaling was not observed to associated with the RET-p75 
complex. Experiments performed and data provided by Chris Donnelly. 
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Figure 3.5: Conditional deletion of Ret results in a reduction in the number of 
cleaved caspase-3 positive cells at E19.5. (A) Representative images of Retfl/fl and 
Retfl/fl;UBC-Cre/ERT2 E19.5 SCGs with DAPI to label nuceli and cleaved caspase-3 
staining to label actively dying cells. Embryos received tamoxifen from E14.5 to E17.5. 
Scale bars denote 200 µm. (B) Quantifications of the number of cleaved caspase-3 
positive cells per area (5 SCGs per genotype, one-tailed, paired t-test; p=0.0420). (C) 
Spinal cords were isolated from Retfl/fl and Retfl/fl;UBC-Cre/ERT2 embryos, and knockdown 
of RET was analyzed. We found that greater than 95% of RET was eliminated in 
Retfl/fl;UBC-Cre/ERT2 spinal cords compared to Retfl/fl littermate controls. 
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Figure 3.6: Conditional deletion of p75 does not result in a reduction of the number of 
cleaved caspase-3 positive cells at E19.5. (A) Representative images of p75fl/+ and p75fl/-
;UBC-Cre/ERT2 E19.5 SCGs with DAPI to label nuceli and cleaved caspase-3 staining to 
label actively dying cells. Embryos received tamoxifen from E14.5 to E17.5. Scale bars 
denote 200 µm. (B) Quantifications of the number of cleaved caspase-3 positive cells per 
area (3 SCGs per genotype, one-tailed, paired t-test; p=0.2515). (C) Spinal cords were 
isolated from p75fl/+ and p75fl/-;UBC-Cre/ERT2 embryos, and knockdown of p75 was analyzed. 
We found that greater than 90% of p75 was eliminated in p75fl/-;UBC-Cre/ERT2 spinal cords 
compared to p75fl/+ littermate controls. 
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Figure 3.7: Germline deletion of p75 does not result in a reduction of cleaved 
caspase-3 positive cells at E19.5. (A) Representative images of p75+/+ and p75-/-
E19.5 SCGs with DAPI to label nuceli and cleaved caspase-3 staining to label 
actively dying cells. Scale bars denote 200 µm. (B) Quantifications of the number 
of cleaved caspase-3 positive cells per area (3 SCGs per genotype, one-tailed, 
paired t-test; p=0.3935). (C) Spinal cords were isolated from p75+/+ and p75-/-
embryos, and knockdown of p75 was analyzed. We were unable to detect any p75 
protein band in p75-/- spinal cords whereas a p75 band was present in p75+/+ 
littermate controls. 
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CHAPTER 4 
 
DISCUSSION 
 
Exon Skipping in RET Encodes Novel Isoforms that Differentially Regulate RET 
Signal Transduction: Discussion and Future Directions  
In this thesis I have shown that RetΔE3 and RetΔE345 transcripts, which were 
originally identified in humans, are conserved in zebrafish, mice and rats.  We 
additionally observed that these mRNAs are expressed dynamically throughout nervous 
system development in mice.  Interestingly, I found that the RetΔE3 and RetΔE345 
transcripts encoded full-length RET proteins in all species analyzed, but with deletions 
in the extracellular domain.  I assessed species conservation because transcripts that 
are highly conserved between multiple species usually play an important role for the 
organism.  Furthermore, RET43, an additional RET transcript that arises from 3’ 
alternative splicing, has only been observed in humans, and I wanted to confirm that 
RETΔE3 and RETΔE345 were not solely human RET transcripts (Myers et al., 1995, Lee et 
al., 2003).   
For the RetΔE3 and RetΔE345 expression experiments, I evaluated tissues where 
full-length RET was expressed because the original expression studies performed in 
humans also analyzed tissues in which RET is known to be expressed, such as the 
kidney and substantia nigra. RETΔE3 and RETΔE345 are co-expressed in these tissues 
(Lorenzo et al., 1995, Ivanchuk et al., 1998). Analyzing additional tissues where RET is 
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not known to be expressed to see if RETΔE3 and RETΔE345 are expressed independently 
of full length RET would be intriguing. Additionally, Lorenzo et al. found an increase in 
expression of RETΔE3 and RETΔE345 in human pheochromocytomas compared to normal 
tissues (Lorenzo et al., 1995).  From these observations, it would be interesting to 
determine if the 5’ alternative splicing that occurs in RETΔE3 and RETΔE345 is enhanced 
in a disease setting.  The RNA splicing machinery may become unregulated in disease 
contexts, allowing for the formation of these RET transcripts that, when translated, give 
rise to proteins that enhance tumor progression.  This idea will be discussed further in 
this chapter. 
In accordance with the low transcript expression of RetΔE3 and RetΔE345, I 
struggled to observe RETΔE3 and RETΔE345 protein isoforms in mouse tissues.  I scaled 
up our protocols to isolate RET from larger volumes and higher concentrations of total 
protein, including tissues of the brain and spinal cord, in the hope that I would isolate 
enough protein of these lower expressed isoforms. While I have observed molecular 
weight RET proteins that run at the appropriate molecular weight for RETΔE345, I have 
not been able to isolate enough protein to successfully confirm by protein sequencing 
and/or mass spectrometry the identity of these protein bands. Additionally, technical 
complications related to the glycosylation of RET arose in our collaborations with the 
University of Michigan Proteomics Core and the Harvard University Proteomics Core, 
and so far I have been unable to detect RET protein via liquid chromatography mass 
spectrometry (LC-MS) from tissues in which RET has been immunoprecipitated. Follow 
up experiments are being performed to determine if RETΔE3 and RETΔE345 are 
expressed in normal tissues. 
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As for additional experimental methods to detect the RETΔE3 and RETΔE345 
isoforms, we created isoform specific antibodies against the amino acids at the exon-
exon junctions of these proteins.  I performed control experiments in which NIH/3T3 
cells were transfected with expression plasmids encoding RET51ΔE3 and RET51ΔE345.  
RET proteins were isolated 48 hours post-transfection via immunoprecipitations using a 
RET51 specific antibody.  Western blot analyses using RET isoform-specific antibodies 
failed to detect the recombinant RET51ΔE3 and RET51ΔE345 proteins. 
Because these deletions in the extracellular domain are highly conserved, we 
were interested in understanding the signaling capabilities and biological functions 
these proteins may possess. We assessed this by first determining if these RET 
isoforms were trafficked to the cell surface, given that mutations in RET, such as 
M918T, have been shown to create unstable proteins that are not trafficked as 
efficiently (Runeberg-Roos and Saarma, 2007). Utilizing two different approaches, a cell 
surface biotinylation assay (data not shown) and an immunocytochemistry approach 
(Fig. 2.3), I successfully detected RET51ΔE3 and RET51ΔE345 at the cell surface.   
Once I determined that the RET isoforms were trafficked to the plasma 
membrane, I wanted to determine whether they could interact with GPI-anchored GFRα 
co-receptors. Interactions with the GFRαs would be required in order for RETΔE3 and 
RETΔE345 to function as receptors for the GFLs.  Although the affinity for the GFRαs is 
increased in the presence of ligand, overexpression of the GFRαs and RET in an in 
vitro, cell transfection setting allows for the interaction of these proteins that are 
otherwise thought to be kept separate under physiologic conditions by lipid rafts 
(Tansey et al., 2000). I hypothesized that both RETΔE3 and RETΔE345 would be able to 
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interact with all four GFRαs since the necessary domains, specifically CLD4 and the 
CRD, are present in both isoforms. Indeed, we did observe interactions between 
GFRα1, GFRα2, GFRα3 and GFRα4 with both RETΔE3 and RETΔE345. However, 
questions still remain unanswered about how the deletions in the extracellular domains 
of these RET isoforms affects the binding affinity of the GFRαs. I am currently 
investigating this question using an enzyme-linked immunosorbent assay (ELISA) in 
which GFRα1 fused to human IgG1 Fc is added with or without GDNF at differing 
concentrations to cells expressing RET, or to RET protein lysates.  An antibody against 
human IgG conjugated to horseradish peroxidase (HRP) is then added, and binding is 
assessed using a colorimetric readout.  Our preliminary experiments show that RETΔE3 
and RETΔE345 bind to GFRα1-Fc and GFRα1-Fc with GDNF, but with lower affinity than 
full-length RET.  Because RETΔE3 retains much of the extracellular domain and can 
potentially function as a receptor for the GFLs, our hope is to use different GFRα-Fc 
recombinant proteins and their cognate ligands to determine if RETΔE3 has a higher 
affinity for selective GFL-GFRα binary complexes. 
We showed that RETΔE3 and RETΔE345 can bind to all four GFRαs, but are they 
able to signal? As a first step, we asked this question using a ligand independent 
approach.  Overexpression of RET in transfected cell lines allows for ligand-
independent association of RET monomers, which induces dimerization and 
autophosphorylation of the proteins.  We assessed the amount of activation by 
quantifying the level of phosphorylated RET versus the total amount of RET. In our 
transfected cell line approach, we found that RETΔE3 is phosphorylated to a similar level 
as full-length RET. However, RETΔE345 displays higher baseline autophosphorylation at 
	   111	  
both the catalytic tyrosine, Tyr905, and also on an additional signaling tyrosine, Tyr1062.  
This was not surprising given we had hypothesized that, due to the large structural 
deletions in the extracellular domain including the calcium binding domain, RETΔE345 
likely acts as a constitutively active form of RET.  While this information was informative, 
we were still interested in addressing if RETΔE3 and RETΔE345 could be activated in a 
ligand-dependent manner. 
Technical difficulties arose while trying to develop a ligand-dependent RET 
activation system in vitro.  Preliminary experiments in NIH/3T3 cells suggested that the 
RETΔE3 isoform could be activated in a ligand-dependent manner.  However, the 
RETΔE345 was not activated in a ligand-dependent manner, as expected, and also 
exhibited increased phosphorylation overall in either the absence or presence of GDNF. 
Replication of this result in transfected NIH3T3 cells was unsuccessful, and countless 
troubleshooting attempts were made to re-establish this technique. We recently 
established a modified ligand-induced activation assay in Neuro2A cells, but the basal 
phosphorylation levels remain too high for us to observe ligand-dependent 
phosphorylation of RET. As an alternative, we have assessed two additional factors as 
a readout of RET activation: (1) ligand dependent association of GFRα1 with RET, and 
(2) ligand-dependent poly-ubiquitination of RET. RET is poly-ubiquitinated following 
activation to signal internalization and degradation of the protein by the proteasome to 
limit the signaling life of the receptor (Tsui-Pierchala et al., 2002). Our preliminary 
results using this assay suggest our earlier findings were correct – RETΔE3 can be 
activated in a ligand-dependent manner while RETΔE345 is not. In our new assay, we 
observe a ligand-dependent association of GDNF-GFRα1 with both RETΔE3 and 
	   112	  
RETΔE345, which was surprising. However, RETΔE3 appears to become poly-
ubiquitinated within 30-60 minutes after GDNF treatment, similar to full-length RET, but 
RETΔE345 does not become poly-ubiquitinated in a ligand-dependent manner (data not 
shown).  
Taken together, these isoforms may have unique and important unidentified roles 
in the development and maintenance of the nervous system and renal system, and may 
also be involved in the pathophysiology of neuroendocrine gland diseases, and as such, 
a number of interesting questions still remain. 
 
Future Directions: 
Further exploration of RetΔE3 and RetΔE345 in neuroendocrine gland tumors 
The alternative splicing that gives rise to RETΔE3 and RETΔE345 was first observed 
in adrenal gland tumors, but only expression of the transcripts was determined (Lorenzo 
et al., 1995). No experiments were performed to determine if these transcripts, which 
seemed to have a higher relative expression in pheochromocytomas compared to 
normal tissues, could be detected at the protein level in these human tumor samples 
(Lorenzo et al., 1995).  It would be intriguing to determine whether RETΔE3 and RETΔE345 
could be isolated from human pheochromocytoma tissues, which may be pursued in the 
future, potentially via the University of Michigan Adrenal Biorepository Effort, although 
our initial attempts to procure samples were unsuccessful. It would also be interesting to 
take advantage of pheochromocytoma cell lines to assess the signaling and the function 
of RETΔE3 and RETΔE345 in a disease context. I would recommend that two different 
experimental designs be used: 
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In the first set of experiments, a pheochromocytoma cell line that does not 
overexpress RET could be used, as not all pheochromocytomas do, such as PC-12 
cells (Powers et al., 2003, Powers et al., 2009). These cells would be co-transfected 
with one of the RET isoforms and GFRα1, and then stimulated with GDNF.  Driving RET 
activation in pheochromocytoma cell lines causes differentiation of the cells to a more 
neuronal-like morphology (Powers et al., 2009). Quantification of the number of 
differentiated cells could then be analyzed as a physiological readout of RET isoform 
signaling.  Additionally, the transfections and GDNF stimulations in this cell line could be 
assessed as an additional in vitro ligand-dependent activation system, and biochemical 
analysis of phospho-RET levels could be determined via immunoblotting, if there is not 
the problem of excessive levels of basal Ret autophosphorylation. 
In the second set of experiments, a pheochromocytoma cell line that does 
overexpress RET could be used.  Since RETΔE3 and RETΔE345 transcripts were detected 
in adrenal gland tumors that overexpress RET, this cell line could be used to determine 
if the RETΔE3 and RETΔE345 isoforms are present.  Initial experiments would need to be 
performed to determine if RETΔE3 and RETΔE345 transcripts are present, initially by 
performing Western blotting to detect full-length RET and the presence of smaller 
molecular weight RET proteins. If RET bands of the appropriate molecular weight are 
present, siRNAs which target the exon-exon junctions of RETΔE3 and RETΔE345 could be 
used to determine if these lower molecular weight RET proteins are truly the RETΔE3 
and RETΔE345 isoforms.  Additionally, if these isoforms are detected, a number of 
experiments could be performed to determine the pathobiological functions of these 
proteins in an in vitro context, including analysis of phospho-RET levels before and after 
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GDNF stimulation as well as investigating the adaptors proteins that interact with each 
RET isoform. 
 
Identifying the mechanism by which exon skipping in RET is regulated 
As mentioned previously, the RETΔE3 and RETΔE345 transcripts are upregulated in 
adrenal gland tumors, but the reason for this has not been elucidated (Lorenzo et al., 
1995). My preliminary bioinformatics analysis predicts several exonic splicing enhancers 
in exons 3, 4 and 5 (data not shown). In cells that endogenously express RETΔE3 and 
RETΔE345 transcripts, it would be exciting to mutate these 6-bp sites with a 
CRISPR/Cas9 system to create synonymous mutations that do not affect the amino 
acid sequence. The expression levels of RETΔE3 and RETΔE345 transcripts could then be 
analyzed by qPCR; by mutating these sites, we would expect to lose expression of 
these alternatively spliced transcripts. Additionally, if a pheochromocytoma cell line 
were observed to have increased expression of RETΔE3 and/or RETΔE345, it would be an 
attractive system to investigate essential pre-mRNA splicing factors, such as SR 
proteins, involved in exon skipping of these RET transcripts. 
 
Interrogating the biological function of the RETΔE3 and RETΔE345 isoforms 
We have so far been unable to successfully establish an experimental system 
that is capable of generating a ligand-dependent physiological readout of RET 
activation, a problem that is not new to the field of RET biology. Important questions, 
however, still remain regarding the function of RETΔE3 and RETΔE345. Can they support 
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cell survival? Are they needed for differentiation of specific cell types?  Do they function 
in axon guidance? 
To address their role in cell survival, primary sympathetic neuron cultures may be 
able to be utilized.  SCGs from UBC-Cre/ERT2; Retfl/fl mice could be isolated and 
cultured, and then treated with 4-hydroxy-tamoxifen to conditionally delete Ret. This 
would bypass the developmental period when RET is necessary for proper development 
of the SCG. Endogenous RET could then be replaced by transducing the cells with a 
virus encoding RETΔE3 or RETΔE345.  These primary sympathetic neurons could then be 
treated with anti-NGF to block survival signaling and stimulated with GDNF to assess 
the amount of cell survival via RET activation.  Full-length RET can support the survival 
of approximately 30-50% of mouse neurons in vitro (Yu et al., 2003). We performed 
preliminary experiments in which primary sympathetic neurons were treated with 
lentiviruses to deliver HA epitope tagged full-length RET, RETΔE3 or RETΔE345 to SCG 
neurons. We observed, however, little to no expression of our exogenous RET isoforms 
in these cells.  Surprisingly, it appears that sympathetic neurons do not express proteins 
well when driven by a CMV promoter, which was the promoter we used given that it is 
the most common promoter in lentiviral vectors. Using a GFP-encoding lentiviral vector, 
SCG neurons seem to express proteins consistently using the neuron-specific promoter 
Synapsin (Fig. 4.1).  Further troubleshooting of this system remains to be completed, 
but this may be the most ideal in vitro system to interrogate the signaling and function of 
RETΔE3 or RETΔE345 in primary neurons.  It should be noted that we also attempted to 
express these RET splice variants in SCG neurons using HSV expression vectors, 
which use the chicken β-actin promoter, but the expression was so robust and rapid  
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Figure 4.1: Infections of primary neuronal cells with lentivirus. (A) Primary sensory 
neurons isolated from the dorsal root ganglia were infected with a 1:1000 dilution of lentivirus 
delivering expression of GFP driven from the Synapsin promoter.  We observed robust GFP 
expression in both sensory and sympathetic neurons treated with this lentivirus after 72 hours. 
(B) Primary sympathetic neurons isolated from the superior cervical ganglia were infected with 
a 1:50 dilution of lentivirus delivering expression of HA epitope tagged RET isoforms driven 
from the CMV promoter. Expression of the RET isoforms was observed after 7 days, however 
the treatment with this concentration of lentivirus negatively affected the viability of the 
neurons.  This is likely due to the high titer of lentivirus needed to successfully express the 
RET isoforms. 
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(high levels within 4-6 hours) that the ectopically expressed RET proteins were highly 
autophosphorylated, as in cell lines (Fig. 4.2). 
Additionally, the ability of RETΔE3 and RETΔE345 to support the differentiation of 
cells could be investigated. The differentiation of the neuroblastoma cell line, Neuro2A 
(N2A), has been used as a physiological readout of proper RET signaling (Tansey et al., 
2000). N2As express low levels of RET and do not express GFRαs.  These cells, 
however, are highly transfectable, and transfection with an expression plasmid encoding 
GFRα1 allows for GDNF-induced activation of RET (Tansey et al., 2000). This activation 
induces N2As to differentiate into a more neuronal-like phenotype in which cells extend 
neurite-like projections within 24-48 hours (Tansey et al., 2000). 
Initial experiments should be performed in which cells are transfected with 
GFRα1, and then stimulated with GDNF, to obtain a baseline level of differentiation.  
Cells could then be transfected with either full-length RET, RETΔE3 or RETΔE345 and the 
level of differentiation examined without any additional experimental treatments.  An 
interesting question to ask first is whether RETΔE345 can induce differentiation in the 
absence of ligand and/or a GFRα.  From our experiments thus far, it seems that 
RETΔE345 may function as a constitutively active receptor, and we predict that cells 
expressing RETΔE345 to differentiate in the absence of ligand and co-receptor.  In the 
next experiments, cells would be co-transfected with full-length RET, RETΔE3 or 
RETΔE345 and GFRα1, and then ligand-dependent differentiation would be assessed. 
Ultimately we are interested in determining whether these splice variants have 
physiologic functions in vivo.  To this end, I recommend the use of one of two possible 
transgenic strategies.  The first would take advantage of the mutations to the 6 bp  
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Figure 4.2: Ectopic expression of RET51ΔE345 does not alter ligand-dependent 
activation of endogenous RET. Sympathetic neurons were infected with HSV to 
deliver RET51ΔE345 to cells.  We observed very robust expression of RET51ΔE345 within 
8 hours after infection and additionally RET51ΔE345 was also highly 
autophosphorylated. Interestingly, immunoprecipitations for RET9 and 
immunoblotting for RET revealed an interaction between endogenous RET9 and 
exogenous RET51ΔE345.  Expression of RET51ΔE345 with endogenous RET9 and 
RET51 did not appear to have any effect on the activation of either protein in the 
presence or absence of GDNF. 
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exonic splicing enhancers described previously.  Knock-in mutations of these enhancers 
would presumably eliminate, or at least significantly reduce, the production of a specific 
splice variant without altering the production of full length RET.  A second approach 
would be to produce knock-in mice in which the intron between exons three and four, or 
between exons five and six, would be removed in frame such that the splicing could not 
occur to produce RETΔE3 and RETΔE345, respectively. The CRISPR/Cas9 system would 
be an ideal method for the production of such mice.  Once these mice were made and 
they were confirmed to be deficient in the targeted splice variant, we would initially 
examine kidney morphogenesis, enteric nervous system development and motor axon 
guidance into the hindlimbs.  
 
Further investigation of the alternative splicing creating a truncated RET isoform 
Lorenzo et al. also detected an additional exon-skipping event in which exons 3 
and 4 were excised (Lorenzo et al., 1995).  This deletion causes a shift in the reading 
frame of the transcript, resulting in the insertion of a premature stop codon.  This 
potential protein product would be very small, mainly encoding a portion of CLD1 and a 
small portion of CLD3. While this transcript would likely undergo nonsense-mediated 
decay, our preliminary experiments suggested that this isoform, RETΔE34, may function 
to enhance the signaling of full-length RET.  Additionally, like RetΔE3 and RetΔE345, 
RetΔE34 was also present in zebrafish, mice and rats, and its expression was also 
dynamically expressed throughout development in mice (Fig. 4.3). A number of 
experiments could be performed to interrogate the function of this isoform, and the 
potential role that it plays during development of the nervous and renal systems.   
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Figure 4.3: RETΔE34 is expressed during development in multiple species and the 
protein augments full-length RET activation in vitro. (A) RT-PCR analysis of Ret 
transcripts in Danio rerio (48 hpf) and Rattus norvegicus (E19.5 spinal cord). (B) qPCR 
analysis of Ret and RetΔE34 in developing brain, spinal cord and DRG. (C) NIH/3T3 cells co-
transfected with RETΔE34 exhibit increased phosphorylation of full-length RET as well as 
interacting adaptor proteins. (D) Primary sympathetic neurons treated with or without RETΔE34 
conditioned medium in the presence or absence of GDNF.  Neurons receiving both RETΔE34 
conditioned medium and GDNF had higher levels of phosphorylation of smaller molecular 
weight proteins, which are likely interacting adaptor proteins. 
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Loss of RET Results in a Decrease in Apoptosis during Programmed Cell Death: 
Discussion and Future Directions 
We discovered that Ret is expressed in a subset of sympathetic neurons of the 
SCG during PCD that also express both p75 and tyrosine hydroxylase, and additionally 
we observed that these Ret positive neurons are lost during this developmental time 
window. Enomoto et al. showed previously that a subset of cells in the developing SCG 
express Ret during PCD using the RetTGM mouse in which GFP was knocked into exon 
1 of RET and expression was driven by the endogenous promoter (Enomoto et al., 
2001). The authors observed in RetTGM/TGM mice that this subset of cells in the SCG still 
upregulated Ret in this null background, and that the percentage of cells upregulating 
Ret in either RetTGM/TGM or RetTGM/+ mice did not differ (Enomoto et al., 2001). Upon 
examination of whether these neurons died upon the deletion of Ret in the RetTGM/TGM 
mice, the authors did not see co-immunostaining between GFP and the apoptotic 
marker cleaved caspase-3. The authors interpreted these results that these Ret positive 
cells were not dying, thus RET was not supporting their survival.  Our approach, 
however, let us distinguish if these Ret positive cells were being lost over time, and we 
did observe a large reduction in the number of Ret positive cells during our pulse 
experiments.  Thus we postulated that Ret was a “marker” for a subset of dying cells in 
the SCG or that RET could potentially be participating in programmed cell death during 
PCD.  
Since RET has not been implicated to function as a death receptor, we sought to 
determine whether it was functioning in conjunction with p75, a member of the TNF 
receptor family, which functions to eliminate “losing” neurons during PCD in the SCG 
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(Bamji et al., 1998, Teng et al., 2010). Since p75 has been found to interact with other 
receptors, including other RTKs such as TrkA, we determined if p75 and RET could 
interact.  Using a transfected NIH/3T3 system, we observed interactions between p75 
and both RET isoforms.  Furthermore, we found in cultured sympathetic neurons that 
the interaction between RET and p75 was enhanced by apoptotic stimuli such as α-
NGF, BDNF and proBDNF.  This suggested that RET may be able to enhance the 
function of p75-mediated cell death in vivo.  
Importantly, we found through the genetic deletion of Ret in developing embryos 
that loss of RET leads to a reduction in cell death during PCD.  Surprisingly however, 
genetic deletion of p75, utilizing both a tamoxifen inducible Cre recombinase approach 
as well as a germline deletion approach, showed no difference in the amount of cell 
death occurring, as assessed by the number of activated caspase-3 positive cells, 
between mutant or control animals. 
It is worth noting that a majority of the research on the role of p75 in cell death 
during PCD has utilized a germline mouse model in which exon 3 of p75 is removed, 
referred to as p75ΔExon3/ΔExon3.  However, von Schack et al. detected a transcript in 
p75ΔExon3/ΔExon3 mice corresponding to the skipping of exon three, which still created a 
full-length p75 transcript, but with deletions in the extracellular domain of p75, termed s-
p75 (von Schack et al., 2001).  These deletions were predicted to inhibit the binding of 
p75 to the neurotrophins, and the authors observed no specific neurotrophin binding of 
NGF, BDNF, NT-3 and NT4/5 in 293 cells expressing recombinant s-p75 (von Schack et 
al., 2001).  Brain and spinal cord samples were used to detect the p75ΔExon3/ΔExon3 
transcript, but these tissues were not analyzed for the translated protein product, and 
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the authors do not address this. Instead, total protein extracts from primary Schwann 
cells were prepared from either wild-type mice or p75ΔExon3/ΔExon3 mice, and by Western 
blot it was shown that a smaller protein product corresponding to the correct molecular 
weight of s-p75 was detected from p75ΔExon3/ΔExon3 mice (von Schack et al., 2001).  The 
authors commented that the wild-type cells express high levels of FL-p75, which masks 
detection of s-p75 due to differences in the glycosylation state of FL-p75 (von Schack et 
al., 2001).  However, this argument could have been strengthened if the authors had 
performed deglycosylation of p75 to demonstrate that this was in fact the case. 
Surprisingly, the Western blot that the authors provide in the figure clearly does not 
show a smaller molecular weight band in the wild-type sample, and the authors do not 
analyze any other tissues other than primary Schwann cells for the detection of the s-
p75 protein product (von Schack et al., 2001).  The authors went on to create a new p75 
null mouse in which exon 4 was targeted for deletion, and these mice presented with a 
considerably worsened phenotype compared to the p75ΔExon3/ΔExon3 mice (von Schack et 
al., 2001).   
Further investigation by Paul et al. argued that there was no 62 kDa molecular 
weight s-p75 band detected from p75ΔExon3/ΔExon3 mice (Paul et al., 2004).  These data, 
however, are complicated by the fact that the authors used high percentage SDS page 
gels when running the protein samples, so there is not a good separation of protein 
bands at the 60-80 kDa range, thereby making it quite difficult to decipher between 
bands that are 62 kDa and 75 kDa (Paul et al., 2004).  While only light exposures of the 
p75 Western blots were provided, Paul et al. did investigate the expression of the s-p75 
isoform in a number of tissues, and they reported not detecting a corresponding lower 
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molecular weight band (Paul et al., 2004).  In the p75ΔExon4/ΔExon4 mouse, the authors did 
detect a lower molecular weight band of 26 kDa, containing the extracellular stalk region 
and the entire intracellular domain of p75 (Paul et al., 2004).  It was shown that this 
truncated p75 protein was able to activate apoptotic p75 signaling cascades, leading to 
increased cell death signaling and a more severe phenotype in these mice (Paul et al., 
2004).  Although these two different mutant mouse strains illuminated new functions of 
p75, the controversy still remains unresolved about the presence of multiple p75 
isoforms and their potential functions. 
To circumvent these issues, Bogenmann et al. created a p75 null mouse model 
in which exons 4-6 were targeted for deletion and germline mice (p75-/-), or mice with a 
conditional p75 allele (p75fl/fl), were generated (Bogenmann et al., 2011).  The germline 
p75-/- mice exhibited a similar phenotype to the p75ΔExon3/ΔExon3 mice.  Importantly, p75fl/fl 
mice crossed to a Wnt1-Cre driver, where Wnt1-Cre can induce recombination in early 
migratory neural crest cells (NCCs), showed loss of p75 in the dorsal root ganglion 
(DRG), while its expression in the lateral motor column was unaffected (Bogenmann et 
al., 2011).  Due to the controversy that has surrounded the use of the other p75 
knockout mouse models, we used the mice generated by Bogenmann et al., both p75-/- 
and p75fl/fl mice, for our experiments.  These mice, however, have not been analyzed to 
determine if PCD is delayed in the SCG, as has been previously found in p75ΔExon3/ΔExon3 
mice (Bamji et al., 1998, Deppmann et al., 2008).   
 One reason we may not detect a significant difference in cell death in our p75 
null animals is because we examined the wrong time point for cell death in regards to 
p75 function.  Although we chose E19.5 because it is the reported height of 
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programmed cell death in the SCG, previous experiments by Bamji et al. reported that 
in p75ΔExon3/ΔExon3 mice, sympathetic neurons of the SCG do not decrease in number 
from postnatal day P1 to P21, which they deemed the normal period of naturally 
occurring cell death (Bamji et al., 1998).  In support of this, Majdan et al. showed a 
significant decrease in TUNEL staining of p75ΔExon3/ΔExon3 SCGs in postnatal day 2 (P2) 
mice compared to wild-type P2 mice (Majdan et al., 2001).  Additionally, Deppmann et 
al. reported that at E18 there is no significant difference in neuron number between 
wild-type and p75ΔExon3/ΔExon3 mice (Deppmann et al., 2008). However, by P0, there was 
a significant increase in the total number of cells in the SCG of p75ΔExon3/ΔExon3 mice as 
compared to wild type mice.  From these examples, it may be that we were too early in 
development to observe differences in naturally occurring cell death that are related to 
p75 function.  Importantly, we reasoned when designing these experiments that since 
our readout for apoptosis marks cells actively undergoing cell death (cleaved caspase-
3), that this would serve as an earlier marker of apoptosis rather than waiting until the 
cells had fully been eliminated (and would then be observed by total cell counts, as the 
p75 knockout studies have generally reported). An important future direction will be to 
repeat these experiments with our p75-/- and p75fl/fl mice at a later, postnatal time point 
and assess if we observe a delay in PCD that has been previously reported (Bamji et 
al., 1998, Deppmann et al., 2008). 
Our in vivo data suggest that RET is not enhancing p75-mediated cell death in 
vivo, at least during the time period from E14.5-E19.5, because the loss of p75 does not 
affect cell death during this time. The important question remains – what is the role of 
RET during this period from E15.5-E19.5, when Ret expression becomes restricted to a 
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subset of cells in the SCG (Enomoto et al., 2001)?  One hypothesis is that during this 
period just after the massive innervation of targets by sympathetic axons, a population 
of these neurons is not receiving enough NGF from their targets to support survival. 
These cells may upregulate Ret in an attempt to continue axonal pathfinding in order to 
innervate another target that will provide the appropriate amount of NGF they need to 
survive. In this scenario, the deletion of Ret starting right at the beginning of this period 
may cause neurons that upregulate Ret and revert back to this axon pathfinding 
phenotype to undergo cell death earlier than expected.  In this case, deletion of Ret 
could cause a bolus of cell death to occur earlier in development, which is missed in our 
experiments because we analyze the SCGs later at E19.5.  Although it is more 
challenging, these experiments could be initiated again at E14.5 and the SCGs could be 
analyzed at E16.5.  Because the SCG has not fully migrated to its final proper position 
at this time point, we would need to section whole embryos and perform 
immunofluorescence staining for tyrosine hydroxylase (to distinguish the SCG from 
surrounding structures), PECAM-1 as a marker for the vasculature, and cleaved 
caspase-3 to label apoptotic cells. The SCG uses cues from blood vessels (ARTN) to 
promote its proper migration, thereby making PECAM-1 an ideal marker to locate the 
migrating SCG. Retfl/fl and UBC-Cre; Retfl/fl mice would again be used, and cleaved 
caspase-3 would be analyzed as a readout for cell death.  If this hypothesis is correct, 
we would expect to see an increase in cell death in SCGs from UBC-Cre; Retfl/fl mice. 
Interestingly, our results in vitro suggest that RET enhances p75-mediated cell 
death in primary sympathetic neurons, although almost all cells are Ret positive in our 
culture system, unlike what we observe in vivo. Our data further indicate that deleting 
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Ret decreases the amount of p75-mediated apoptosis in vitro, but the loss of Ret does 
not completely block cell death (Chris Donnelly, unpublished data). In fact, p75-
mediated cell death still occurs in the absence of Ret in vitro, but it is delayed, and not 
as effective, as when RET is expressed. While primary sympathetic neurons have been 
a useful system to study RET signal transduction, they may not be the most accurate 
system to understand the function of RET during PCD.  It is also possible that RET has 
more than one function during the period of PCD, an earlier function in survival that we 
uncovered in these experiments, and a later p75-dependent cell death function that will 
be revealed by looking at postnatal cell death time periods. In addition, a number of 
interesting questions still remain to be answered.  
 
Future Directions 
Determining if there are differences in programmed cell death between p75ΔExon3/ΔExon3, 
p75-/- and UBC-Cre/ERT2; p75fl/fl mice 
 The p75 germline and conditional mice generated by Bogenmann et al. were not 
analyzed to determine if PCD was occurring in the SCG in a manner that was previously 
described (Bamji et al., 1998, Deppmann et al., 2008).  To fully examine this, SCGs 
from p75-/- and wild-type littermates should be isolated at previously described intervals, 
from E18.5 to P21, and total cell counts, as well as cleaved caspase-3 counts, should 
performed to assess PCD in these mice.  Additionally, it would be intriguing to look at a 
few earlier time points in the SCG between p75-/- and wild-type littermates, such as 
E16.5 and E17.5, to assess the amount of cell death occurring before birth. This 
experiment, while time consuming, would help establish the entire period of PCD, and 
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determine what the appropriate readout of cell death should be – total cell counts or 
cleaved caspase-3 immunostaining. 
Determining the protein domains necessary for the interactions of p75 and RET 
As stated previously, p75 is a very promiscuous receptor.  It has been found to 
interact with a number of other proteins including TrkA, Nogo receptor, Ephrins and 
Sortilin (Meeker and Williams, 2014). It would be interesting to determine whether the 
binding region that has been identified for TrkA and p75, especially since TrkA is an 
RTK, is similar in amino acid composition or structure to the binding region for RET and 
p75. This information would also be useful to better understand how p75 has the ability 
to interact with so many receptors.   
Interrogating p75-RET interactions in other tissues derived from neural crest cells  
In addition to our findings reported here, the interaction between p75 and RET 
appears to enhance the differentiation and maintenance of non-peptidergic nociceptors 
in the dorsal root ganglion during development (Chris Donnelly, Kuo Fen Lee; 
unpublished data).  Because DRG sensory neurons are also derived from the neural 
crest similar to sympathetic neurons, it would be interesting to investigate other tissues 
derived from NCCs to determine whether p75 and RET function together as a complex, 
either p75 enhancing the pro-survival function of RET or RET enhancing the pro-
apoptotic function of p75.  One interesting tissue to begin with would be the enteric 
nervous system. It would be exciting to determine if p75 enhances RET dependent 
enteric neural crest-derived cell (ENCC) migration during development, or if RET 
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enhances p75-mediated cell death such as in Hirschsprung’s disease (Huang et al., 
2015). 
Larger implications of this research 
RTKs regulate numerous cellular processes including cell survival, metabolism, 
proliferation and differentiation throughout development and adulthood of many 
organisms. Mutations that affect the activity, abundance, cellular distribution or 
regulation of these receptors often leads to diseases such as cancer, making our 
understanding of the basic biology of these receptors, especially the regulation of their 
expression and signaling, critically important. In this context, understanding the 
regulation of RET via novel mechanisms, such as those discussed in this dissertation, 
is essential. Along with future studies, I hope these data will further our understanding 
of RET biology under both physiologic and pathologic conditions. 
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